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SUMMARY  
This thesis investigates prognostic factors influencing outcome and survival in 
patients managed by the South East Wales Upper GI cancer network. The 
hypotheses tested were: Socio-economic deprivation and health deprivation 
adversely influence outcome in patients undergoing surgery for oesophageal and 
gastric cancer; Patient delay accounts for the majority of the total delay encountered 
in the diagnosis and treatment of oesophago-gastric cancer and deprivation is an 
important factor in this regard; Body composition and sarcopenia as measured by 
Bioelectrical Impedance Analysis (BIA) are important prognostic indicators; 
Centralisation of oesophago-gastric cancer services significantly improves outcome 
and survival. 
In a consecutive cohort of 1185 patients survival was associated with multiple 
deprivation (P<0.0001) and health deprivation (P<0.0001). Total delay consisted of 
the following components: patient delay (76%); practitioner delay (1%) and hospital 
delay (23%). Factors influencing patient delay were deprivation (p=0.005) and 
gender (p=0.030). Survival was significantly related to overall delay (p=0.010). In 125 
patients who underwent BIA testing open and close laparotomy was significantly 
associated with FFM% (p=0.027), and BF% (p=0.030). Post-operative morbidity 
(Clavien-Dindo ≥3) was associated with intracellular fluid volume (ICV) (p=0.018), 
total body water content (p=0.019), and sarcopenia (p=0.045). Critical care length of 
stay was associated with ICV (p=0.009), lean muscle mass (p=0.006), the phase 
angle (p=0.025) and sarcopenia (p=0.011). Treatment with curative intent increased 
from 21.6% to 29.6% of patients before and after centralisation respectively 
(p=0.002). Serious post-operative morbidity (Clavien-Dindo ≥ 3) decreased after 
centralisation (p=0.194), and there were significant reductions in critical care length 
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of stay (p<0.0001), with overall length of hospital stay reduced by 2.5 days (p= 
0.008). On univariate analysis of factors influencing two-year survival centralisation 
was statistically significant (p=0.001). 
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Chapter 1  
Introduction and a review of the literature 
1.1 Historical Perspective 
The earliest written description of oesophageal cancer appears to come from Egypt 
between 3000 and 2500BC after the discovery in 1862 of an ancient manuscript 
known as the Smith Surgical Papyrus. The document contains a case entitled “A 
Gaping Wound of the Throat Penetrating the Gullet” and includes the clinical 
observations, anatomy, and pathology of oesophageal cancer (Eslick 2009). Reports 
of oesophageal cancer also appear in China over 2000 years ago where it was 
referred to as “Ye Ge”, meaning dysphagia and belching, and the authors at the time 
suggested this particular cancer was the result of “heavy indulgence of heated 
liquors” (Qian 1961). The Roman physician and philosopher Galen (125-200 AD) 
subsequently published work describing the possibility of a fleshy growth partially or 
completely obstructing the passage of food down the gullet. 
The word oesophagus is derived from the ancient Greek oisophágos, oisein meaning 
to carry and phagos meaning food. Middle age developments in the understanding 
and treatment of oesophageal cancer include the suggestion by the Spanish 
physician Avenzoar (1090-1162) to “introduce food into the stomach by a silver tube 
and the use of nutritive enemata”, and the subsequent development of the 
oesophagoscope by Kussmaul (1822-1902) in 1868. Kussmaul’s son-in-law Vincenz 
Czerny (1842-1916) performed the first successful resection of a human cervical 
oesophageal carcinoma in 1877, after which the patient survived for 1 year. 
In 1946 Ivor Lewis, a pioneering Welsh surgeon trained in Cardiff, revolutionised 
oesophageal surgery after performing an oesophagectomy and oesophago-
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gastrectomy through a right thoracotomy. Lewis published his seminal paper “The 
surgical treatment of carcinoma of the oesophagus with special reference to a new 
operation for growths of the middle third” in which he described seven such cases 
with an operative mortality of 29% and five-year survival of 19% (Lewis 1946). 
Humphrey Bogart, a renowned heavy drinker and smoker, died from oesophageal 
cancer in 1957, and the last words he uttered were “I should never have switched 
from scotch to martinis”. 
The first possible reference to gastric cancer dates back to 1600 BC and was 
reported in the Ebers papyrus, found with an ancient Egyptian mummy at Luxor in 
1873. The prominent Arabic physician and philosopher Avicenna also described a 
gastric cancer in his 11th century publication Medical Encyclopaedia. Further 
understanding of gastric anatomy and disease was however curtailed throughout the 
Dark and the Middle Ages due to the Catholic Church’s prohibition of the 
examination of human corpses, and the main anatomical reference for those times 
was the anatomy of a monkey’s stomach, described by Galen (Santoro 2005). It was 
only in the 18th century, and particularly during the Renaissance, that medieval 
concepts changed and theories regarding the origins of cancer were modified.  
The modern concept of oncology was first proposed in a thesis entitled “Dissertatio 
Accademica de Cancro” by Peyrile in Lyon in 1774. Throughout the 18th century 
however, gastric cancer remained enigmatic until the description of benign and 
malignant gastric ulcers by Cruveilhier in 1835. In the interim, Napoleon Bonaparte 
died in May 1821 suffering from abdominal pain, vomiting, anorexia and diarrhoea. 
On autopsy a “cancerous ulcer” was discovered but debate persists to this day as to 
whether he died from gastric cancer or he was the victim of chronic arsenic 
poisoning. The French surgeon Jules Emile Pean performed the first gastric 
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resection for cancer in 1879 but the patient only survived until the 5th post-operative 
day.  
The first successful operation, a subtotal resection with gastro-duodenal 
anastomosis, was performed in January 1881 by Theodor Billroth in Vienna. The 
patient was a 43-year-old female who had presented with gastric outlet obstruction 
secondary to a pyloric carcinoma. In modern terms the tumour would be described 
as a T3N2/3 Stage IIIb mucinous adenocarcinoma. The patient was discharged 26 
days post-operatively but died of recurrence after some 4 months. When he retired 
fourteen years later Billroth had performed a total of 257 sub-total gastrectomies. 
The first total gastrectomy was performed in 1897 by Karl Schlatter, a 32 year old 
surgeon working in Zurich. He performed a total gastrectomy and oesophago-
jejunostomy on a 56-year-old woman for a diffuse gastric cancer. The patient 
survived for 14 months before also succumbing to recurrent disease. These initial 
advances have since culminated in the contemporary practice of gastrectomy with 
radical D2 lymphadenectomy. Notable people to have died from gastric cancer 
include the actor John Wayne and the Irish writer James Joyce. 
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1.2 Epidemiology 
1.2.1 Oesophageal Cancer 
Oesophageal cancer, including both adenocarcinoma and squamous cell carcinoma 
(SCC), is the 8th most common cancer worldwide and ranks sixth in terms of 
mortality (Zhang 2013). Oesophageal adenocarcinoma was once an exceedingly 
rare histological type of oesophageal cancer but the incidence has increased greatly 
in recent times, by up to 600% since the 1970s (Rubenstein 2015). On a global scale 
however, SCC remains the predominant form (Arnold et al. 2014).  In 2011 there 
were 8,332 new cases of oesophageal cancer in the UK accounting for nearly 3% of 
all new cases: 5,582 (67%) in men and 2,750 (33%) in women (Cancer Research UK 
2015). 
1.2.2 Gastric Cancer 
According to the most recent estimates from the International Agency for Research 
on Cancer (IARC), gastric cancer is now the fifth most common cancer in the world 
after lung, breast, colorectal and prostate cancer respectively, with nearly one million 
new cases and 723,000 deaths in 2012 (Ferlay et al. 2013). The disease accounted 
for 7% of the total new cancer cases and 9% of the total cancer deaths, with over 
70% of these deaths occurring in less developed regions (Oh et al. 2014). In the UK 
there were just over 7,000 new cases of gastric cancer diagnosed in 2011, 
accounting for 2% of all new cases: 4,615 (65%) in men and 2,474 (35%) in women 
(Cancer Research UK 2015). 
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1.3 Aetiology 
1.3.1 Oesophageal Adenocarcinoma 
The prevalence of oesophageal adenocarcinoma is increasing rapidly in Western 
society, presumably linked to the concurrent obesity epidemic. Recognised risk 
factors include gastro-oesophageal reflux disease (GORD), obesity, tobacco use, 
increasing age, and male gender. Furthermore, the disease is most common in 
industrialised countries with populations of predominantly Northern European origin 
(Bosetti et al. 2008). Barrett’s oesophagus, whereby the normal squamous 
epithelium is replaced by specialised intestinal columnar epithelium, is the only 
known precursor lesion for this cancer (Rubenstein 2015).  
Barrett’s oesophagus develops secondary to GORD when recurrent reflux causes 
erosive oesophagitis and, after an aberrant healing process in predisposed 
individuals, the normal squamous cell lining of the distal oesophagus is replaced by 
a metaplastic columnar-lined epithelium (Souza et al. 2008). Previous research has 
shown a two to four-fold increased risk of developing cancer in patients with a history 
of GORD (Chow et al. 1995). Moreover, there is a linear relationship between risk of 
malignancy and severity of GORD as patients with recurrent and prolonged 
symptoms have an 8-fold increased risk of developing adenocarcinoma compared 
with patients who have minimal symptoms (Lagergren et al. 1999). The development 
of adenocarcinoma in a Barrett’s segment follows a progressive sequence from 
intestinal metaplasia to low grade dysplasia (LGD), then high grade dysplasia (HGD) 
and finally to cancer (Jankowski et al. 1999).  
Obesity contributes to the development of a tumour by two mechanisms; mechanical 
and hormonal. Obesity–related hiatal herniation increases the risk of GORD with 
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resultant recurrent erosive oesophagitis. From a hormonal perspective obesity is 
associated with insulin resistance which in turn is linked with multiple epithelial 
cancers and the metabolic syndrome (Drahos et al. 2014; Lindkvist et al. 2014). 
Obesity also causes altered levels of circulating peptide levels which in turn are 
associated with Barrett’s oesophagus (Garcia et al. 2014). Alcohol use and 
Helicobacter pylori however, are thought to protect against adenocarcinoma 
(Freedman et al. 2011; Islami et al. 2008). 
1.3.2 Oesophageal Squamous Cell Carcinoma 
Alcohol and tobacco are the main risk factors for SCC, and oesophageal squamous 
dysplasia has been identified as the precursor lesion. Patients with mild, moderate or 
severe dysplasia have a 3, 10 or 30 fold greater risk respectively of developing SCC 
(Wang et al. 2005). Oesophageal SCC is three to five times more likely among 
people who consume three or more alcoholic drinks daily (Rustgi and El-Serag, 
2014), and up to seven times more likely in people who smoke tobacco (Kamangar 
et al. 2009). Furthermore, there appears to be a synergistic effect between the two 
whereby individuals who drink more than 1.5 bottles of wine and smoke 10 to 30 
cigarettes daily have approximately a 150-fold increased risk (Salaspuro 2003).  
Achalasia, an oesophageal motility disorder which causes oesophagitis due to stasis 
and resultant fermentation of food residue, is associated with a ten-fold increased 
risk of developing oesophageal SCC (Zendehdel et al. 2011). The rare autosomal 
dominant disorder Tylosis Palmaris et Plantaris, and Paterson-Brown-Kelly 
syndrome characterised by an inherent epithelial atrophy or hyperkeratinisation are 
also associated with developing oesophageal SCC (Blaydon et al. 2012; Chisholm 
1974). In addition, the tumour suppressor gene p53 has been found to be abnormal 
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and responsible for the aberrant progression from normal oesophageal mucosa to 
cancer in up to half of cases of oesophageal SCC (Casson et al. 1998).  
1.3.3 Gastric Cancer 
Gastric carcinoma has a complex and multifactorial pathogenesis with both an 
environmental and genetic aetiology. It was previously thought that N-nitroso 
compounds (mostly nitrosamines) were the principal causal factor but no proof of this 
causality has been found. In more recent times the emphasis on investigation has 
shifted to bacterial aetiology, and more specifically the role of Helicobacter Pylori 
(H.Pylori) (Correa and Schneider, 2015). In 1994 the IARC classified H. pylori as a 
class I human carcinogen (IARC 1994). The chronic active inflammatory response to 
the infection caused by H. Pylori is thought to induce gastric neoplasia via both the 
immune response elicited and the resulting damage from oxidative stress. More 
latterly, the long suspected influence of genetic susceptibility and the role of 
polymorphisms in the inflammatory cytokine genes of the host have come to the 
forefront (Correa and Schneider, 2015). The gastric microenvironment and acid 
secretion are also thought to play a key role in the pre-cancerous process. Patients 
with gastric ulcers have a tendency towards hypochlorhydria and the pro-
inflammatory cytokine Interleukin-1β. IL1β is a potent inhibitor of acid secretion (100 
times more potent than proton pump inhibitors), and previous studies investigating 
the IL1β gene cluster in gastric cancer patients have shown a four-fold increased risk 
of developing a tumour (El-Omar et al. 2003).  
Gastric cancer has also been attributed to a number of dietary and lifestyle factors. 
Salted, smoked and preserved foods are associated with an increased risk of gastric 
cancer, whereby prolonged or excessive consumption leads to atrophic gastritis and 
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the generation of carcinogenic N-nitroso compounds (Gore 1997). Cigarette smoking 
is associated with a 2 to 3 times increased risk of proximal gastric cancer (Devisa et 
al. 1998; Haung et al. 2000).  
The US National Cancer Institute examined ethnicity as a risk factor for gastric 
cancer and found people of Japanese and Korean origin at particularly high risk 
compared with Caucasians. Gastric carcinoma can occasionally develop in families 
with germline mutations in the p53 tumour suppressor gene, e.g.; Li-Fraumeni 
syndrome and BRCA2, or as part of the hereditary non-polyposis colon cancer 
(HNPCC) syndrome, familial adenomatous polyposis (FAP) and Peutz-Jeghers 
syndrome (Fenogilo-Preiser et al. 2000). Other factors associated with an increased 
risk of gastric cancer include chronic atrophic gastritis (e.g. pernicious anaemia), 
previous gastric surgery, hypertrophic gastropathy (Metenier’s disease), gastric 
polyps, low socioeconomic status, and obesity (Gore 1997).  
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1.4 Diagnosis 
1.4.1 Symptoms 
The most important prognostic factor in patients diagnosed with oesophageal or 
gastric cancer is the stage of disease at presentation, yet incurable metastatic 
disease is still diagnosed in as many as 50% of patients at first presentation (Allum 
et al. 2002). Patients with upper gastrointestinal cancer typically present with 
dyspepsia, progressive dysphagia often associated with weight loss and fatigue, or 
on occasion with iron deficiency anaemia.  
British Society of Gastroenterology (BSG) guidelines recommend that all patients 
over 55 years of age with recent onset dyspepsia, and all patients with alarm 
symptoms suggestive of UGI cancer irrespective of age should be referred for rapid 
access endoscopy and biopsy (Allum et al. 2011). Moreover, the UK Department of 
Health has specified that these urgent investigations be performed within two weeks 
of referral (Dept of Health 2000).  
1.4.2 Screening 
At present there is no screening programme for UGI cancer in the UK, but in 
countries with a high burden of disease such as Japan and the Republic of Korea 
barium-meal photofluorography and upper endoscopy were introduced in 1960 and 
1999 respectively. The relative 5-year survival rates for gastric cancer in these 
countries is around 70%, compared with less than 30% in most other countries 
without national screening programmes (Park et al. 2014). Endoscopic screening 
and non-endoscopic balloon brush cytologic testing have previously been performed 
in regions of China and may have merit (Rustgi and El-Serag 2014).  
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For patients with known Barrett’s oesophagus however, endoscopic surveillance is 
recommended every three years. Patients in whom adenocarcinoma is detected 
through surveillance for Barrett’s are more likely to have early-stage disease, receive 
curative therapy, and survive longer than patients who present with symptoms and in 
whom cancer is then subsequently detected (Kearney et al. 2003; Cooper et al. 
2009).  
1.4.3 Endoscopy 
The gold standard for diagnosis of UGI cancer is oesophagogastro-duodenoscopy 
(OGD), allowing direct visualisation of the lesion and biopsy or cytological brushings 
for histological confirmation. As discussed previously the UK Department of Health 
has recommended patients older than 55 years of age with new onset or persistent 
dyspepsia, or patients of any age who present with alarm symptoms should undergo 
endoscopy, and furthermore recommends these investigations be performed within 
two weeks of referral (Allum et al. 2011). For patients suspected of having a gastric 
tumour endoscopy is the most sensitive and specific method of diagnosis (Karpeh et 
al. 1998).  
In cases where OGD is not indicated or tolerated a barium swallow will outline any 
mucosal irregularities or strictures, but carries the inherent disadvantage of being 
unable to obtain a biopsy for histological diagnosis. Barium studies for the detection 
of carcinoma of the oesophagus and oesophago-gastric junction have been found to 
have a positive predictive value of 42% (Levine et al.1997). 
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1.5 Staging Classification 
1.5.1 Tumour Nodes Metastases (TNM) Classification 
The contemporary TNM classification system for staging solid tumours was originally 
devised by Professor Pierre Denoix between 1946 and 1952 (Denoix 1946) and has 
subsequently been accepted for use by the Union for International Cancer Control 
(UICC) and the American Joint Committee on Cancer (AJCC). The TNM system 
describes the anatomic extent of cancer and is based on three factors; the size and 
extent of the primary tumour (T stage), the number of regional lymph node 
metastases (N stage), and the presence or absence of distant metastases (M stage). 
Such an accurate and unified classification system facilitates the planning of 
appropriate treatment, estimating prognosis and exchange of information between 
trial centres.  
1.5.2 T Stage 
The T stage describes the depth of invasion of the primary tumour and is essentially 
similar for both oesophageal (Table 1.1) and gastric cancer (Table 1.2). The least 
invasive tumours are limited to the lamina propria and/or the submucosa and are 
classified as T1 tumours. Tumours which invade the muscularis are T2, T3 tumours 
traditionally invaded the serosa or adventitia for gastric or oesophageal cancers 
respectively, and T4 tumours have spread to invade adjacent structures. 
The 7th edition of the TNM classification system however introduced some 
modifications whereby T3 gastric cancer represents subserosal invasion, T4a 
serosal penetration and T4b invasion of adjacent structures. For oesophageal 
cancer, Tis denotes carcinoma in-situ or HGD, T1a represents invasion of the lamina 
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propria, and T1b submucosal invasion. T4 has been sub-classified whereby T4a 
represents invasion of the pleura, pericardium, peritoneum or diaphragm and T4b 
invasion of the aorta, trachea or bone (Sobin 2009). Early tumours confined to the 
mucosa and submucosa have previously been shown to confer a significantly better 
prognosis than more advanced tumours (Tachibana et al. 2000), and T stage has 
been found to be an independent predictor of survival after surgery (Khan et al. 
2004). 
1.5.3 N Stage 
The N stage describes the extent or absence of regional lymph node metastasis and 
is used to determine the most appropriate treatment using multi-modal therapy 
(Mariette et al. 2003; Kunisaki et al. 2005). A description of the TNM 7 N stage 
classification for oesophageal and gastric cancer is provided in Tables 1.1 and 1.2 
respectively.  
By tradition an operable tumour has been defined as of radiological stage N0 or N1 
(Earlam 1980). The accuracy of the N stage is dependent on the number of lymph 
nodes harvested, and a minimum count of 10 nodes should be examined to 
designate stage N0 in oesophageal cancer (Twine et al. 2009) and 15 nodes for  
gastric cancer  (Bouvier et al. 2002). Furthermore, the number of malignant lymph 
node metastases is a key prognostic factor predicting outcome after surgical 
resection for oesophageal cancer (Kawahara et al. 1998). In oesophageal disease 
carcinomas arising in the upper oesophagus drain to cervical or upper mediastinal 
nodes while those arising from the mid or lower oesophagus spread to lower 
mediastinal or perigastric nodes, and skip metastases are not infrequent (Glickman 
2003). 
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1.5.4 M Stage 
The M stage is the assessment of distant metastases whereby M0 represents 
tumours with no metastases and M1 tumours with distant metastases. In gastric 
cancer the M stage is simply divided into M0 and M1 representing the absence or 
presence of distant metastases respectively. This classification has now also been 
adopted in staging oesophageal cancer whereby metastases in the coeliac lymph 
nodes are no longer classified as M1a (Sobin 2009), thereby simplifying 
oesophageal cancer into M0 or M1, as for gastric cancer. 
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Table 1.1 TNM 7 for Oesophageal cancer  
T stage                                                           N Stage 
Tis = Carcinoma in-situ 
T1a Tumour invades Lamina propria             N1=1-2 nodes 
T1b Tumour invades Submucosa                  N2=3-6 nodes 
T2 Tumour invades Muscularis propria          N3=>6 nodes  
T3 Tumour invades Adventitia  
T4a Tumour invades pleura, pericardium, peritoneum, diaphragm 
T4b Tumour invades trachea, aorta, vertebrae 
Table 1.2 TNM 7 for Gastric Cancer  
T stage                                                          N Stage  
T1a Tumour invades Lamina propria             N1=1-2 nodes  
T1b Tumour invades Submucosa                  N2=3-6 nodes  
T2 Tumour invades Muscularis propria         N3a=7-15 nodes  
T3 Tumour invades subserosa                      N3b=16 nodes  
T4a Tumour perforates serosa  
T4b Tumour invades adjacent structures 
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1.6 Pre-operative Staging 
Approximately 50% of patients with upper GI cancer have metastatic disease at first 
presentation, and the two most important prognostic indicators for oesophageal 
cancer are depth of tumour penetration and lymph node involvement (Iyer 2004). 
Initial assessment must therefore stage the disease as accurately as possible in 
order to determine which patients may be suitable for surgical resection. In the case 
of early tumours precise localised staging is performed to assess suitability for 
endoscopic mucosal resection (EMR). For more advanced tumours depth of invasion 
with reference to surgical margins, clear delineation of cranio-caudal and radial 
margins, and the presence and extent of lymph node metastases are assessed 
before tailoring an individual patient’s treatment. The principal imaging modalities are 
computed tomography (CT), positron emission tomography combined with CT 
(PET/CT), endoscopic ultrasonography (EUS) and diagnostic laparoscopy. 
1.6.1 Computed Tomography 
The first line of multimodal investigation is CT imaging of the thorax, abdomen and 
pelvis to look for metastatic disease. CT studies should be performed with 
intravenous contrast and anti-peristaltic agents may be given to achieve maximum 
distension. CT has limited value in staging early disease due to an inability to reliably 
delineate the individual layers of the oesophageal wall and therefore cannot 
distinguish between T1 and T2 lesions. The use of CT multi-planar images combined 
with axial imaging however is particularly accurate when differentiating between T3 
and T4 disease as the multi-planar re-formatted images increases the ability to 
determine any loss of the fat plane around the oesophagus and stomach (Bhandari 
et al. 2004). The reported accuracy of CT in diagnosing mediastinal invasion ranges 
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from 59% to 82% (Saunders et al. 1997; Rankin 1998). The accuracy in predicting 
lymph node metastases in the abdomen is in the order of 85% (Saunders et al. 
1997), and the overall accuracy of CT for predicting regional lymphadenopathy 
ranges from 50% to 70% (Iyer 2004). The main strength of CT is the detection of 
distant metastases with a sensitivity and specificity of 52% and 91% respectively 
(van Vliet et al. 2008). Small volume metastatic disease can however be missed by 
CT and investigations such as PET/CT and laparoscopy can improve the accuracy of 
M staging. 
1.6.2 Positron Emission Tomography  
Positron Emission Tomography (PET) is a nuclear medical imaging technique which 
uses a labelled glucose analogue, 2-[18F] fluoro-2-deoxy-D-glucose (18F-FDG), 
combined with CT imaging to provide both functional and anatomical data. The 
radioactive tracer 18F-FDG is taken up by the more metabolically active tumour 
cells, the rate of uptake being proportional to metabolic activity, and malignant 
tumours usually have higher metabolic rates compared with normal tissue 
(Branstetter et al. 2005). The main advantage of PET/CT is that the patient position 
remains unchanged between each procedure thereby allowing for reliable co-
registration of the PET and the CT data. For previously unsuspected metastatic 
disease PET/CT significantly improves detection rates with a sensitivity of 69-78% 
and specificity of 82-88% (Allum et al. 2011), and establishes a more advanced 
stage in 10-20% of cases (Rustgi et al. 2014). 
 PET/CT also has potential benefits when planning radiation therapy as it is now 
possible to treat tumours while reducing radiation doses to non-target organs 
compared with traditional techniques (Allesio et al. 2004). However, studies with 
20 
 
PET/CT have reported a failure to detect early stage tumours (T1 and T2) and 
mucinous tumours (Allum et al. 2011). Furthermore, while PET/CT can identify local 
lymph node metastases, avid uptake by the adjacent  tumour can obscure uptake in 
nearby small volume metastatic lymph nodes, and The American College of Surgical 
Oncology Group trial of PET to identify unsuspected metastatic lesions 
demonstrated a 3.7% false-positive and a 5% false negative rate (Meyers et al. 
2007). 
1.6.3 Endoscopic Ultrasonography 
Endoscopic ultrasonography is most accurate for T staging in more advanced 
tumours because of the precise visualisation of the individual layers of the 
oesophageal and gastric walls. A previous meta-analysis found EUS could detect 
T1b disease with 80% sensitivity and 70% specificity, and the added ability to 
perform fine needle aspiration further improves the sensitivity of lymph node staging 
(van Vliet et al. 2008). EUS has previously been shown to be the most accurate 
method of assessing nodal status (Foley et al. 2014), and on meta-analysis the 
sensitivity and specificity of detecting regional lymph node metastases is also 
reported as 80% and 70% respectively (van Vliet et al. 2008). The accuracy of 
overall N-staging is 66%, compared with 68% for PET/CT (Choi et al. 2010).  
Further to these diagnostic roles, EUS defined tumour characteristics such as 
tumour length (Twine et al. 2010), total length of disease (Davies et al. 2012), and 
tumour volume (Twine et al. 2010) also provide important prognostic information.  
EUS is limited however as an imaging modality if strictures prevent passage of the 
scope to the full extent of the tumour, and dilatation carries a high risk of perforation 
(Pfau et al. 2000). EUS is not suitable for M staging, but in combination with fine 
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needle aspiration it is an accurate and safe method for the assessment of solid 
lesions such as liver metastases or for aspiration of ascites (Wallace et al. 2001; 
Eloubeidi et al. 2004). 
1.6.4 Staging Laparoscopy 
Staging laparoscopy should be undertaken in all gastric cancers and in selected 
patients with lower oesophageal and oesophago-gastric junctional tumours (Allum et 
al. 2011). Laparoscopy may establish the presence of previously undetected 
peritoneal or pancreatic metastases in addition to assessing the operability of locally 
spread disease. Previous studies have shown laparoscopy provided additional 
treatment information in 17% of distal oesophageal and oesophago-gastric junctional 
tumours and 28% of gastric tumours (de Graaf et al. 2007). 
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1.7 Risk Stratification 
Despite the increased efficacy associated with chemoradiotherapy, oesophagectomy 
remains the mainstay of potential curative treatment for oesophageal cancer. 
Oesophagectomy is however, a highly invasive procedure with serious potential 
post-operative complications including pneumonia, anastomotic leak, and sepsis. A 
McKeown total oesophagectomy involves entering three separate body cavities, and 
trans-thoracic oesophagectomy with 3-field lymph node dissection is one of the most 
invasive gastrointestinal operations performed (Fujita et al. 1995; Kinugasa et al. 
2004; Fang et al. 2007). Upper gastrointestinal cancer resection therefore falls within 
the category of high risk surgery as defined by the Royal College of Surgeons of 
England (RCSE 2011). In order to predict and thereby protect patients at greater risk 
of post-operative morbidity and mortality there are several operative risk stratification 
tools including the American Society of Anaesthesiologists (ASA) Physical Status 
Classification System, the Physiological and Operative Severity Score (POSSUM), 
and Cardio-Pulmonary Exercise Testing (CPEX). 
1.7.1 American Society of Anaesthesiology Physical Status Classification 
The ASA system was designed in 1963 to assess the fitness of patients pre-
operatively and uses a six category classification system as follows: 
I equates to a normal healthy patient,  
II equates to mild systemic disease, 
III equates to severe systemic disease, 
IV equates to severe systemic disease that is a constant threat to life,  
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V equates to a moribund patient not expected to survive without operation,  
VI equates to a patient declared braindead awaiting organ removal for donor 
purposes (Dripps, 1963). Although used globally the correlation of ASA grade with 
peri-operative risk does however have limitations. It does not consider inter-tester 
reliability between individual anaesthetist`s assessments when describing common 
clinical problems (Daabiss, 2011), nor does it consider the nature of the planned 
operation, the skill of the anaesthetist or the surgeon, or the post-operative facilities. 
1.7.2 Physiological and Operative Severity Score  
The POSSUM system was devised in 1991 and uses linear analysis, based on 12 
physiological and 6 operative variables, to give a predicted risk of operative morbidity 
and mortality (Copeland et al. 1991). A strength of the POSSUM model is the 
combined assessment of physiological status (physiological score) with a measure of 
the magnitude of a particular operation (operative severity score). Though widely 
used and validated in many surgical specialities POSSUM has been reported to 
have a poor predictive accuracy related to oesophagectomy (Zafirellis et al. 2002). A 
modified O-POSSUM version was therefore subsequently derived specifically for 
oesophago-gastric surgery (Tekkis et al. 2004). The value of the various POSSUM 
models in oesophago-gastric surgery however remains controversial, with some  
studies finding O-POSSUM to be of greater predictive accuracy (Bosch et al. 2011), 
while others continue to debate the degree of overestimation of mortality risk 
(Nagabushan et al. 2007; Lagarde et al. 2007; Dutta et al. 2010).  
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1.7.3 Cardiopulmonary Exercise Testing 
CPEX is a non-invasive, dynamic and objective measurement of cardiovascular and 
respiratory function during exercise that can be used to assess the ability of a patient 
to adapt to the increased oxygen demand required during and following surgery 
(Saito et al. 2007). A reduced anaerobic threshold, the point at which increasing 
exercise results in oxygen consumption exceeding supply and a consequent switch 
to anaerobic metabolism, has been reported to predict greater mortality following 
major abdominal surgery (Older et al. 1999). Further physiological variables 
measured by CPEX include the peak oxygen uptake (VO2 max) and ventilatory 
equivalent for carbon dioxide (VE/VCO2). Few studies have investigated the 
association between CPEX derived variables and outcome in oesophago-gastric 
cancer surgery. Previously VO2 max has been reported to be significantly lower in 
patients who experience cardiopulmonary morbidity following oesophagectomy 
(Nagamatsu et al. 1994 and 2001; Forshaw et al. 2008), but there remains a need 
for a large-scale study of CPEX in oesophago-gastric surgery (Hennis et al. 2011). 
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1.8 Bioelectrical Impedance Analysis 
Patients with upper gastrointestinal cancer and particularly patients with 
oesophageal or junctional tumours are at significant risk of dysphagia, weight loss 
and cachexia. It has been reported that cachexia itself rather than the underlying 
tumour is responsible for a significant number of cancer-related deaths (Ottery 
1994). Sarcopenia has been defined as the degenerative loss of skeletal muscle 
mass, quality, and strength and is often a component of cachexia. 
A deficiency in pre-operative nutritional status (malnutrition) is associated with higher 
rates of surgical morbidity and mortality (Deans et al. 2007), but is also potentially 
identifiable and reversible.  Considering UGI cancer resection falls within the Royal 
College of Surgeons of England (RCSE 2011) category of high risk surgery, it is 
clearly important therefore to formulate tailored nutritional regimes for each patient 
undergoing such major procedures. 
One such method of determining nutritional status is Bioelectrical Impedance 
Analysis (BIA). This is a non-invasive, easily reproducible and inexpensive means of 
accurately measuring body composition parameters including fat free mass, 
percentage body fat, percentage lean muscle mass, and intracellular and 
extracellular water volume. Furthermore, the phase angle (PhA), as measured by 
BIA, is a reflection of cell membrane resistance and reactance and has been used to 
determine malnutrition at the cellular level. BIA has previously been used as a 
prognostic marker to predict survival in colorectal and pancreatic cancer (Gupta et al. 
2004), but it`s prognostic role in UGI cancer has not yet been investigated.  
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1.9 Surgical Treatment 
1.9.1 Oesophagectomy 
The aim of curative oesophagectomy is excision of the primary tumour with adequate 
longitudinal and radial resection margins, appropriate lymphadenectomy, and an 
uncomplicated anastomosis with low morbidity. Tumour location, histological type, 
proposed extent of lymphadenectomy and patient co-morbidity determine the 
operative approach.  
There are two standard surgical approaches for oesophagectomy; transhiatal and 
transthoracic. A transhiatal approach involves abdominal and left-sided neck 
incisions and is most appropriate for early stage node negative disease (T1-4, N0), 
HGD, or patients with associated significant co-morbidity who would not withstand a 
thoracotomy. The two-phase transthoracic, or Ivor Lewis approach, is used for 
middle or upper third tumours and is the standard practice in Europe and the United 
States. Additional neck lymphadenectomy is performed in areas where SCC is 
prevalent. The procedure involves a laparotomy and right thoracic approach with the 
anastomosis high in the chest, some surgeons also perform a cervical incision to 
create the anastomosis at this level. This approach facilitates good mediastinal and 
para-oesophageal lymphadenectomy, thereby enabling a large yield of lymph nodes 
for histological assessment.  
Minimally invasive oesophagectomy (MIO) is the most recently described technique 
and involves laparoscopic access to the abdomen and thoracoscopic access to the 
chest. The technique is associated with a quicker recuperation period and can 
potentially harvest an adequate lymph node yield to discern the presence of 
metastatic disease (Luketich et al. 2003; Noble et al. 2013). Each approach has its 
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proponents and there is no level 1 evidence to suggest that any one approach is 
associated with a survival benefit (Rubenstein et al. 2015). Randomised studies 
have however associated a transhiatal approach with less post-operative morbidity 
(Hulscher et al. 2002). 
1.9.2 Gastrectomy 
Gastrectomy with curative intent should be undertaken only after discussion at an 
UGI multi-disciplinary meeting taking into account  all staging information, patient co-
morbidity, nutritional status and patient preference. The type of resection is based on 
the position and staging of the tumour and the extent of the intended 
lymphadenectomy.  
British Society of Gastroenterology and British Association of Surgical Oncology 
guidelines recommend proximal tumours be removed by total gastrectomy, distal 
(antral) tumours be removed by subtotal gastrectomy, and type II oesophago-gastric 
junctional tumours, cardiac and subcardiac tumours be treated by transhiatal 
extended total gastrectomy or oesophago-gastrectomy (Allum et al. 2011). The 
extent of lymphadenectomy is determined by the location and stage of the cancer, in 
a D1 lymphadenectomy the perigastric nodes closest to the primary tumour are 
removed en bloc with the stomach, whereas a D2 lymphadenectomy involves the 
removal of the perigastric and distant nodes along the main arteries supplying the 
stomach (first 2 tiers of lymph nodes, N1 and N2). For patients with stage II and III 
cancers a D2 lymphadenectomy is recommended if performance status allows 
(Allum et al. 2011). A previous Dutch study with long-term follow-up showed better 
cancer-related survival after D2 lymphadenectomy (Songun et al. 2010). A minimum 
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of 15 lymph nodes should be resected for histological examination to ensure 
accurate reliable staging (Sobin et al. 2002).  
Limited gastric resections should be reserved for palliation or very elderly patients 
only. Furthermore, the spleen and splenic hilar nodes should only be resected in 
cases of tumours on the greater curvature or posterior wall of the stomach in close 
proximity to the splenic hilum, and the distal pancreas should only be resected when 
there is direct invasion but the intent of procedure is curative and the tumour is in the 
proximal stomach.  
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1.10 Enhanced Recovery after Surgery 
The concept of Enhanced Recovery after Surgery (ERAS) was first pioneered by 
Kehlet in Copenhagen in patients undergoing colorectal surgery and challenged 
many of the traditional dogmatic aspects of peri-operative care (Basse et al. 2000). 
Conventional peri-operative care surrounding gastrointestinal resection and 
anastomosis was based on prolonged periods of fasting and gastrointestinal tract 
rest until the return of normal gut function, routinely requiring patients to remain in 
hospital for up to 3 weeks, even in the absence of any major complications (Karl et 
al. 2000; Hofstetter et al. 2002).  
 
ERAS described an evidence-based multi-disciplinary package of care for patients 
undergoing colorectal surgery aiming to reduce the stress response to surgery and 
promote the return of normal gut and body function (Fearon et al. 2005). The 
package includes pre-admission patient education, avoidance of pre-operative bowel 
preparation, reduced pre-operative fasting, carbohydrate loading, anti-thrombotic 
and antibiotic prophylaxis, goal-directed anaesthesia and fluid resuscitation, and 
early post-operative enteral nutrition and mobilisation (Basse et al. 2000). The 
efficacy of ERAS has subsequently been demonstrated in large meta-analyses 
which have shown significantly reduced morbidity rates and shortened hospital stay 
following colorectal resection (Gouvas et al. 2009; Varadhan et al. 2010), and now 
represents a mainstay of contemporary colorectal surgical practice. The role of 
ERAS in upper gastrointestinal surgery however is less well established. A recent 
systematic review concluded that experience of ERAS for oesophagectomy 
tentatively suggests that it is feasible and associated with improved levels of 
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morbidity and mortality but the evidence is poor, sparse, and with a dearth of 
evidence for individual components (Findlay et al. 2014; Karran et al. 2016). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
31 
 
1.11 Neoadjuvant Therapy 
The treatment of oesophago-gastric cancer has become more complex due to 
increasing evidence of improved outcomes associated with multimodal therapy, 
rapidly changing patterns of disease, improved staging capability and an increasingly 
elderly and co-morbid population. Surgery with curative intent is restricted to only 
those patients with early stage disease due to the high recurrence rates in advanced 
tumours. The rationale behind neo-adjuvant therapy is to shrink and downstage a 
tumour prior to surgery, thereby increasing the chances of resection and also to treat 
occult metastatic disease and minimise potential for local recurrence. Furthermore, 
by reducing tumour volume a patient may regain the ability to swallow and thereby 
gain weight and improve both their nutritional and performance status.  
The three most recent large trials investigating pre-operative chemotherapy plus 
surgery versus surgery alone have produced conflicting results. The Rotterdam 
Esophageal Tumour Study Group randomised 160 SCC patients to chemotherapy 
plus surgery versus surgery alone. The study showed a significant difference 
(p=0.002) in the median survival between chemotherapy plus surgery and surgery 
alone groups (18.5 months vs. 11 months) respectively (Kok et al. 1997). The 
American Intergroup Trial (INT 0113) randomised 440 patients to chemotherapy plus 
surgery versus surgery alone and found no difference in median survival between 
the groups (16.1 months vs. 14.9 months) respectively, and no difference in 1, 2 and 
3-year survival respectively (Kelsen et al. 1998). However, the UK Medical Research 
Council (MRC) OEO2 study, potentially the largest and arguably the most influential 
trial in the field, randomised over 800 patients to chemotherapy plus surgery versus 
surgery alone. The study reported that overall survival was significantly improved 
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following pre-operative chemotherapy plus surgery (p=0.004), with 5 year survival of 
23% compared with 17% after surgery alone. Furthermore there was no evidence 
that the effect of chemotherapy was influenced by histology (MRC Oesophageal 
Cancer Working Party 2002). Pre-operative chemotherapy is therefore the accepted 
standard of care in the UK as opposed to the US where chemoradiotherapy is the 
standard treatment (Malthaner et al. 2010).  
The recently completed MRC OEO5 trial, comparing OEO2 chemotherapy with four 
cycles of ECX (epirubicin-cisplatin-capecitabine), may alter practice if this regimen is 
found to further improve survival (Allum et al. 2009). Pre-operative chemoradiation 
and pre-operative chemotherapy have not been directly compared in the context of a 
phase III randomised controlled trial and pre-operative radiotherapy is not 
recommended for potentially resectable oesophageal SCC or adenocarcinoma 
(Allum et al. 2011). The advantages associated with pre-operative chemotherapy 
should however be weighed up against potential delay in proceeding to resection 
due to excess toxicity or non-response to chemotherapy (Shapiro et al. 2015).   
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1.12 Definitive Chemoradiotherapy 
Chemotherapy or chemoradiation is a definitive treatment for patients with 
unresectable, metastatic or recurrent disease. For patients with localised 
oesophageal adenocarcinoma unsuitable for surgery, definitive chemoradiation 
(dCRT) is a valid treatment option (Anderson et al. 2007). For localised squamous 
cell carcinoma of the oesophagus dCRT is the current recommended standard of 
care after the 2010 UK National Oesophago-Gastric Cancer Audit (NOGCA) showed 
the disease could be treated by either dCRT or surgery (NOGCA 2010). Indeed in 
upper SCC, dCRT can achieve local control in up to 70% of patients and surgery is 
only reserved as a salvage option (Denham et al. 2003).  
For oesophageal tumours, palliative chemotherapy provides symptom relief and 
improves health-related quality of life (HRQL) in inoperable or metastatic disease, 
and palliative combination chemotherapy improves survival compared with best 
supportive care (Allum et al. 2011). Palliative external beam radiotherapy can relieve 
the dysphagia and pain associated with unresectable oesophageal cancer with 
minimal toxicity, albeit more slowly compared with stent insertion (Caspers et al. 
1988; Cwikiel et al. 1996). Palliative brachytherapy has been shown to improve 
HRQL in cases where a patient is expected to survive for greater than 3 months. For 
patients with HER2-positive oesophago-gastric junctional adenocarcinoma 
trastuzumab in combination with cisplatin and fluoropyrimidine improves disease-free 
survival and overall survival (van Cutsem et al. 2009). Chemoradiation is associated 
with better disease control and improved survival when compared with radiation 
alone, but is associated with greater toxicity (Wong et al. 2006).  While the aim of 
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dCRT is prolongation of survival, overall 5 year survival remains less than 15% 
(Rubenstein et al. 2015).  
For locally advanced and/or metastatic gastric cancer palliative combination 
chemotherapy provides HRQL and survival benefit, increasing survival from 7 to 10 
months compared with 3 to 4 months when treated with best supportive care (Allum 
et al. 2011). Furthermore, combination therapy is superior to single-agent therapy, 
but no international consensus has yet been reached regarding which combination 
regimen should be used first-line. In the UK ECF (epirubicin, cisplatin and infused 5-
FU) has been the preferred regimen to date. 
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1.13 Non-Surgical Treatment 
In Barrett’s oesophagus radiofrequency ablation (RFA) has been reported to 
eradicate oesophageal metaplasia in up to 80% of cases and dysplasia in over 85% 
of cases (Shaheen et al. 2009). Regular endoscopic surveillance is however 
recommended for patients who have undergone RFA for a superficial tumour 
(Orman et al. 2013). Endoscopic cryotherapy and photodynamic therapy have also 
been associated with positive outcomes for patients with early adenocarcinoma but 
data remains limited (Yachimski et al. 2009; Greenwald et al. 2010).  
Endoscopic mucosal resection (EMR) and submucosal dissection (SMD) are also 
used in treating Barrett’s oesophagus with high-grade dysplasia or T1a 
adenocarcinoma. Once the tumour invades the submucosa (T1b) however, the risk 
of lymph node metastasis rises by up to 60% (Gockel et al. 2011). As EMR and SMD 
do not treat regional lymph nodes, their use is therefore limited to T1a tumours. 
Furthermore, SCC of the oesophagus is reputed to be more aggressive than 
adenocarcinoma, patients with T1a adenocarcinoma have a 0% risk of nodal 
metastases vs 18% risk for those patients with SCC tumours  (Eguchi et al. 2006; 
Griffin et al. 2011). EMR and SMD are not therefore used to treat SCC. Patients with 
T1b tumours should undergo oesophagectomy with curative intent. 
Endoscopic management of superficial tumours have reported rates of local control 
greater than 95% (Pech et al. 2014), and several observational studies have 
suggested cure and survival rates are equivalent to those achieved with surgical 
resection (Ngamruengphing et al. 2013). However, endoscopic eradication therapy is 
recommended after complete EMR as over 30% of patients who undergo EMR 
without adjuvant eradication therapy develop recurrent disease (Pech et al. 2014). 
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Additionally, after removing high-risk lesions with EMR or SMD, the mucosa will also 
need to be ablated, most frequently with RFA. 
Obstructive tumours not amenable to resection can be palliated by endoscopic 
placement of covered self-expanding metal stents (SEMS), and their use is 
associated with marked improvement in dysphagia symptoms (Battersby et al. 2012; 
Stewart et al. 2013). In randomised controlled trials SEMS have been found to confer 
greater symptomatic relief with fewer complications requiring re-intervention, and are 
now the first-line palliative option for dysphagia (Zhu et al. 2014).  
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1.14 Deprivation 
Deprivation is a broad concept which includes limited access to the opportunities and 
resources which society might expect such as good health, a clean and safe living 
environment, and protection from crime (Welsh Assembly Government 2011). Eight 
types of deprivation, or domains, have been described including; employment, 
income, education, health, community, geographical access to services, housing, 
and physical environment. Multiple deprivation refers to the different types that might 
occur, and represents a far more profound notion than poverty alone. Deprivation 
varies geographically, and Wales is recognised as having relatively high levels when 
compared with England and several other European countries. Indeed, when 
compared with the UK as a whole, the general health of the population of Wales is 
significantly poorer with more emergency hospital admissions per capita, and an 
overall life expectancy one year shorter when compared with England (National 
Audit Office 2012). 
Linear relationships between levels of deprivation and survival have been reported 
for no fewer than 44 of 47 specific anatomical cancer sites, including oesophageal, 
colon and rectal cancer (Coleman et al. 1999). Deprivation is also associated with an 
increased incidence of upper gastrointestinal cancer (McKinney et al. 1995; Gossage 
et al. 2009) and several reports have highlighted a survival benefit for patients 
residing in less deprived geographical areas when compared with more deprived 
areas (Auvinen et al. 1995; Kogevinas et al. 1997; Stephens et al. 2005). 
Discrepancies in cancer-related survival cannot be explained entirely by differences 
in the stage at diagnosis (Thomson et al. 2001; Hole et al. 2002) or by higher co-
morbidity among patients from deprived backgrounds (Wrigley et al. 2003). 
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Moreover, a widening of survival inequality with time has been reported, whereby the 
improved outcomes experienced by patients living in less deprived geographical 
areas over the past 25 years have not been shared by patients from more deprived 
areas (Coleman et al. 2004). The NHS Cancer Plan of September 2000 (Dept of 
Health 2000), and subsequent government targets introduced in 2003, were aimed 
at reducing such inequalities across the socio-economic divide, and specific and 
demanding NHS targets were set (Dept of Health 2003).   
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1.15 Service Reconfiguration 
Implementation of the Improving Outcomes Guidance (IOG) by the UK Dept of 
Health in 2001, and subsequent NHS re-configuration, has resulted in the 
establishment of 41 specialist centres providing oesophageal and gastric cancer 
care in England and Wales. Centralisation of UGI cancer services has however been 
an issue of ongoing contentious debate since it’s inception, and was only introduced 
in South East Wales at the University Hospital of Wales in August 2010 following a 
period of protracted negotiation between politicians, managers and clinicians. 
Historically the provision of UGI cancer resectional surgery was poorly organised 
and fragmented, undertaken by individual surgeons operating on very small numbers 
of patients. It was associated with a 30 day mortality rate of between 10 to 20% 
(Bachmann et al. 1999; Northern and Yorkshire Cancer Registry and Information 
Service 1999). The rationale behind a centralised service was that UGI cancer 
surgery, amongst the most complex surgical procedures, benefits when performed in 
specialist high-volume centres of excellence (Birkmeyer et al. 2003, Brusselaars et 
al. 2014). The IOG document recommended that these specialist cancer units should 
aim to perform at least 40 oesophagectomies and 60 gastrectomies each year, 
drawing patients from catchment areas with populations of one to two million (Dept 
of Health 2001). More recently the Association of Surgeons of Great Britain and 
Ireland (AUGIS) suggested the ideal unit would have four to six dedicated UGI 
surgeons each performing a minimum of 15 to 20 resections per year (AUGIS 2010).  
The potential disadvantages include increased distance from home for patients, 
greater social isolation, and increased expenses incurred by visiting families. From a 
clinical perspective local district general hospitals are downgraded and lose their 
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cancer workload, waiting times for benign operations potentially increase, and there 
are significant costs associated with implementing a centralised service in a hospital. 
Furthermore, despite having been shown to significantly improve in-hospital and 30 
day mortality, the data regarding long-term survival remains limited and even 
contradictory in some individual studies (Gruen et al. 2009;  Lauder et al. 2010; 
Markar et al. 2012; Tol et al. 2012; Wouters et al. 2012, Lagergren et al. 2013; Chan 
et al. 2013). 
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1.16 Aims and Hypotheses 
In light of the above, this thesis aims to address the following: 
1. To determine the influence of the Index of Multiple Deprivation (IMD) and 
Health Deprivation (HD) on Upper GI cancer treatment outcome. 
 
2. To examine the time taken to diagnose Upper GI cancer, identify sources 
of delay, and assess the prognostic significance of delay. 
 
3. To determine the prognostic value of Bioelectrical Impedance Analysis and 
sarcopenia in Upper GI cancer surgery. 
 
4. To determine the impact of centralisation on Upper GI cancer outcomes 
and survival at two years. 
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The hypotheses tested are:  
1. Socio-economic and health deprivation adversely influence outcome in 
patients undergoing surgery for oesophageal and gastric cancer. 
 
2. Patient delay accounts for the majority of delay in the diagnosis of Upper GI 
cancer, deprivation is an important factor in patient delay, and delay adversely 
influences outcome.  
 
3. Body composition and sarcopenia as measured by BIA are important 
prognostic indicators in patients undergoing Upper GI surgery. 
 
4. Centralisation of oesophago-gastric cancer services improves post-operative 
morbidity, decreases length of hospital stay and improves survival. 
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Chapter 2 
Prognostic significance of deprivation in upper gastrointestinal 
cancer 
2.1 Summary 
The aim of this study was to determine the influence of the Index of Multiple 
Deprivation (IMD) and Health Deprivation (HD) on upper gastrointestinal (UGI) 
cancer outcome.  
Consecutive 1185 patients (697 oesophageal, 488 gastric cancer) were studied 
prospectively. Deprivation scores were calculated using the IMD of the Welsh 
Government. Mortality data were obtained from the Office for National Statistics 
(ONS) and this data, as well as survival data, were independently verified by the 
Welsh Cancer Intelligence and Surveillance Unit.  Primary outcome measure was 
survival from diagnosis.  
Median survival for gastric cancer patients was 8 months (0.25 to 64) compared with 
10 months (0.25 to 62) for oesophageal cancer patients. Open and close laparotomy 
for all surgical patients was commoner in patients residing in deprived geographical 
areas with a 6.5% open and close rate in the least deprived IMD quintile versus 
13.5% in the most deprived quintile (P=0.006). On post-operative histopathology, 
IMD was associated with pT (r=-0.146, P=0.043), pN (r=-0.158, P=0.029), and pM 
stage (r=-0.189, P=0.016). On univariate analysis survival was associated with 
oesophageal versus gastric tumour site (P=0.028), histopathological cell type 
(P<0.0001), age (P<0.0001), radiological (r) TNM stage (P<0.0001), radical 
treatment intent (P<0.0001), IMD (P<0.0001) and HD (P<0.0001). On multivariate 
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analysis of all patients, age (HR 1.021, 95% CI, 1.014-1.028, P<0.0001), rTNM stage 
(HR 1.559, 95% CI, 1.427-1.704 P<0.0001), radical treatment intent (HR 0.338, 95% 
CI, 0.274-0.418, P<0.0001), and IMD rank (HR 1.000, 95% CI, 1.000-1.000, 
P=0.084) were associated with duration of survival. 
In conclusion deprivation is an important prognostic indicator in UGI cancer. 
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2.2 Introduction 
Deprivation is a broad concept which describes limited access to the opportunities 
and resources which society might expect such as good health, a clean and safe 
living environment, and protection from crime (Welsh Assembly Government 2011). 
Eight types of deprivation, or domains, have been described, including; employment, 
income, education, health, community, geographical access to services, housing, 
and physical environment. Multiple deprivation refers to the different types that might 
occur, and represents a far more profound notion than poverty alone. Deprivation 
varies geographically, and Wales is recognised as having relatively high levels when 
compared with England and several other European countries. Indeed, when 
compared with the UK as a whole, the general health of the population of Wales is 
significantly poorer with more emergency hospital admissions per capita, and an 
overall life expectancy one year shorter when compared with England (National 
Audit Office 2012). 
Linear relationships between levels of deprivation and survival have been reported 
for no fewer than 44 of 47 specific anatomical cancer sites, including oesophageal, 
colon and rectal cancer (Coleman et al. 1999). Deprivation is also associated with an 
increased incidence of upper gastrointestinal cancer (McKinney et al. 1995; Gossage 
et al. 2009), and several reports have highlighted a survival benefit for patients 
residing in less deprived geographical areas when compared with more deprived 
areas (Auvinen et al. 1995; Kogevinas et al. 1997; Stephens et al. 2005). 
Discrepancies in cancer related survival cannot be explained entirely by differences 
in the stage at diagnosis (Thomson et al. 2001; Hole et al. 2002) or by higher co-
morbidity among patients from deprived backgrounds (Wrigley et al. 2003). 
Moreover, a widening of survival inequality with time has been reported, whereby the 
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improved outcomes experienced by patients living in less deprived geographical 
areas over the past 25 years have not been shared by patients from the more 
deprived areas (Coleman et al. 2004). The NHS Cancer Plan of September 2000 
(Dept of Health 2000), and subsequent government targets introduced in 2003, were 
aimed at reducing such inequalities across the socio-economic divide, and specific 
and demanding NHS targets were set (Dept of Health 2003). It remains to be 
established whether deprivation per se directly influences outcome in UGI cancer, 
and if so, whether the effect may be analogue or digital in nature. As prognosis for 
patients diagnosed with UGI cancer is often poor, the potential benefit from 
understanding and addressing reversible factors is substantial. The aims of this 
study were to determine the influence of deprivation on outcomes for patients with 
UGI cancer, with particular emphasis on survival following potentially curative 
therapy. The setting was a UK cancer network serving a population of 1.4 million 
people. 
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2.3 Material and Methods 
Between 1st August 2008 and 31st July 2012, a total of 1185 patients were diagnosed 
with UGI cancer and managed by the South East Wales UGI multidisciplinary team 
[median age 72 (22-97) years, 783 male, 402 female, 697 oesophageal, 488 gastric 
cancer, 903 adenocarcinoma (ACA), 206 squamous cell carcinoma (SCC)]. The 
details of these patients were collected prospectively and data was cross-referenced 
with the oncology (CANISC) database. Mortality data were obtained from the Office 
for National Statistics (ONS) and this data, as well as survival data, were 
independently verified by the Welsh Cancer Intelligence and Surveillance Unit. 
Deprivation rankings were designated for each patient using the Welsh Index of 
Multiple Deprivation (IMD) 2011, as determined by the National Assembly for Wales 
(Welsh Assembly Government 2011). This index gives the official measure of 
multiple deprivation for every postcode in Wales and is based on the eight previously 
described forms of deprivation. The country is divided into 1,896 areas each having 
about 1,500 people with the most deprived geographical area ranked 1 and the least 
deprived area ranked 1,896. The IMD for all areas was sub-classified into equally 
sized socio-economic quintiles; the most deprived group was labelled quintile 1, and 
the least deprived quintile 5. These cut-off points allowed subgroup analysis of 
patients from similarly deprived areas while facilitating comparison across the 
spectrum. Health deprivation (HD) was also examined, the indicators for which are 
cancer incidence, all-cause death rate, percentage of live single births <2.5kg, and 
the number of inhabitants with limiting long-term illness per 100,000 of the 
population. HD was similarly sub-classified into equally sized quintiles. 
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2.3.1 Staging investigations 
Patients deemed to have potentially curable tumours underwent diagnostic 
gastroscopy with histopathological confirmation of oesophageal or gastric cancer 
and computed tomography (CT) of the thorax and upper abdomen. Patients selected 
for radical treatment also underwent endoluminal ultrasound (EUS), CT Positron 
Emission Tomography (PET/CT) and laparoscopy, if appropriate. Tumours were 
staged according to the unified TNM classification of UGI cancer edition 6 (Sobin et 
al. 2002) until 2010 and edition 7 (Edge et al. 2010) thereafter. 
2.3.2 Multidisciplinary management 
Patients were initially discussed at one of three local multi-disciplinary team (MDT) 
meetings and if deemed potentially curative they were then referred to and 
discussed at the regional South East Wales UGI MDT meeting. The MDT consists of 
seven specialist upper GI surgeons, oncologists, palliative care physicians, 
radiologists, pathologists, specialist nurses and dieticians. Patients were selected for 
appropriate radical treatment based on histopathological stage, co-morbidity, the 
technical feasibility of surgery and patient choice according to an algorithm described 
previously (Stephens et al. 2006). Those not suitable or in favour of radical therapy 
were offered palliative care by specialist palliative care physicians. 
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2.3.3 American Society of Anaesthesiologists grade 
The ASA grade was calculated for surgical patients as a measure of co-morbidity. 
The system has five grades:  normal healthy individual; mild systemic disease that 
does not limit activity; severe systemic disease that limits activity but is not 
incapacitating; incapacitating systemic disease which is constantly life-threatening; 
moribund, not expected to survive 24 hours. 
2.3.4 Surgical treatment 
Surgery was performed by one or a combination of seven upper gastrointestinal 
surgeons working within the parameters of the MDT. For patients with oesophageal 
cancer a transhiatal resection as described by Orringer was performed in those with 
T1-2, N0 tumours (Orringer 1984). It was also employed selectively for patients with 
adenocarcinomas of the lower third of the oesophagus which were more advanced 
(T3 N1) and for patients with associated significant co-morbidity (ASA grade III). The 
remaining oesophageal cancer patients underwent standard subtotal 
oesophagectomy as described by Lewis or Tanner (Lewis 1946; Tanner 1947). For 
those with gastric cancers it was the policy to perform a modified radical D2 
resection with extended lymphadenectomy but preserving the pancreas and spleen 
where possible (Lewis et al. 2002; Edwards et al. 2004). The definition of a 
potentially curative resection was that all visible tumours were removed and that both 
proximal and distal resection margins were free of tumour on histological 
examination. Morbidity and mortality included all in-hospital complications and 
deaths. Morbidities were recorded against a specific list agreed by all the surgeons 
involved and graded using the Clavien-Dindo Classification of surgical complications 
(Dindo et al. 2004). 
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2.3.5 Definitive chemoradiotherapy (dCRT) 
Patients undergoing dCRT received a treatment protocol which involved four 3-
weekly cycles of cisplatin (dose 60mg/m2) and infusional 5-fluorouracil (5-FU, 
300mg/m2/day). Cycles three and four were given concurrently with five weeks of 
radiotherapy (50Gy in 25F), during which time the 5-FU was reduced to 
225mg/m2/day. If during the course of treatment the glomerular filtration rate (GFR) 
was less than 40ml/min or the patients experienced significant neuro- or 
nephrotoxicity, cisplatin was discontinued and replaced with carboplatin. 
2.3.6 Follow-up 
Patients undergoing surgery were reviewed every three months for the first year and 
every six months thereafter. Definitive chemoradiation patients were followed up by 
the oncologists at equivalent periods. Endoscopy and CT were performed if recurrent 
disease was suspected. Patients treated with palliative intent were followed up by 
both oncology and palliative care physicians. All patients were followed up for a 
minimum of 6 months or until death, and no patients were lost to follow-up. Dates of 
death were obtained from the Office for National Statistics thus ensuring accurate 
survival times and dates of death for all patients. Nine hundred and eighty five 
patients (83.1%) were followed up for two years (n=157) or until death (n=828). 
2.3.7 Statistical Analysis 
Statistical analysis appropriate for non-parametric data was used. Grouped data 
were presented as median (range), and quintiles were grouped to allow accurate 
Cox regression analysis. Bivariate correlations were calculated using Spearman`s 
correlation test. Differences were deemed statistically significant when P<0.05. 
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Cumulative overall survival was calculated by the life-table method of Kaplan and 
Meier (Kaplan et al. 1958). Differences in survival between groups of patients were 
analysed using the log-rank method (Altman 1991). Factors found to be significantly 
associated with duration of survival on univariate analysis and with P-value <0.10 
were entered into a multivariate analysis using Cox’s proportional hazards model. To 
identify any potential confounding factors, a separate stepwise regression was also 
performed using the univariate effect of deprivation as the first step. Data analysis 
was carried out with the Statistical Package for Social Sciences (SPSS) version 20 
package (IBM Corporation, New York). 
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2.4 Results 
Demographic details of the patients related to quintile are presented in Table 1. 
2.4.1 Age at presentation 
There was a direct correlation between age at diagnosis and IMD rank. Median age 
in the most deprived quintile (1) was 72 years (range 22-94) compared with 74 years 
(42-97) for patients in quintile 5 (r = 0.058, P=0.046). There was also a significant 
correlation between age at diagnosis and anatomical site of the tumour whereby the 
median age of patients presenting with oesophageal cancers (including type 1 and 
type 2 junctional tumours) was 71 (24-97) years, compared with 75 (22-97) years for 
patients presenting with gastric cancer, including type 3 junctional tumours (r=0.146, 
P<0.0001). 
2.4.2 Anatomical site of tumour 
There was no significant correlation between the anatomical site of the tumour and 
the IMD (r=-0.003, P=0.905) or HD (r=-0.017, P=0.562). 
2.4.3 Histopathology and stage of cancer at presentation 
Details of patient`s histopathology related to IMD quintile are presented in Table 1.  
There were 903 (76.2%) adenocarcinomas (ACA), 206 (17.5%) squamous cell 
carcinomas (SCC), and the remaining 6.3% comprised of high grade dysplasia 
(HGD), neuroendocrine tumours, or undifferentiated carcinomas. There was a 
significant association between a diagnosis of SCC and lower IMD quintiles (r=-
0.059, P=0.044), and HD quintiles (r=-0.063, P=0.030). Females accounted for 121 
(59%) of the 206 SCC cancers, with males making up the remaining 85 (41%, 
r=0.241, P<0.0001). Radiological staging investigations revealed a strong correlation 
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between EUS defined tumour length and both IMD and HD rank (r=-0.165, P=0.025 
and 0.026 respectively). No correlation was found between the perceived rTNM 
stage at presentation and either IMD (r = -0.054, P=0.089), or HD (r=-0.048, 
P=0.126).  
2.4.4 Details of the surgery 
A total of 229 patients (19.3%) were suitable for radical surgical treatment and their 
details are shown in Table 2. One hundred and nine patients had neoadjuvant 
therapy followed by surgery, and 120 patients had surgery alone. No correlation was 
found between IMD and perceived fitness for surgery as defined by the American 
Society of Anaesthesiology (ASA) grade (r = 0.016, P=0.863). Open and close 
laparotomy for all surgical patients was commoner in patients residing in deprived 
geographical areas with a 6.5% open and close rate in the least deprived IMD 
quintile versus 13.5% in the most deprived quintile (P=0.006). No correlation was 
found between IMD and operative morbidity (41.4% in quintile 1 versus 39.4% in 
quintile 5, r=0.016, P=0.841), or HD and operative morbidity (51.7% in quintile 1 
versus 48.4% in quintile 5, r=0.041, P=0.594) respectively. Furthermore, there was 
no correlation between IMD or HD and operative mortality within 30 days of surgery 
(3.3% in quintile 1 versus 0% in quintile 5, r =-0.077, P=0.318, r=-0.016, P=0.834 
respectively). On post-operative histopathology, IMD was associated with pT (r=-
0.146, P=0.043), pN (r=-0.158, P=0.029), and pM stage (r=-0.189, P=0.016).  
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2.4.5 Palliative treatment 
A total of 857 patients were considered to be of too poor performance status, or were 
diagnosed with tumours of such advanced stage that radical treatment was not 
possible. These patients received palliative chemotherapy, radiotherapy, stent 
insertion or best supportive care in keeping with the patients` wishes. 
2.4.6 Survival 
Median survival from diagnosis for all 1185 patients was 9 (range 0.25 to 64) 
months. Regarding the 229 patients who underwent surgery with curative intent 
median survival was 20 (range 1 to 64) months, and 21 (range 3 to 57) months for 
the 81 patients receiving definitive chemoradiotherapy.  
The duration of survival from diagnosis was significantly associated with both IMD 
(P<0.0001), and HD (P<0.0001). There was a strong correlation between duration of 
survival and IMD for Siewert type I and II oesophago-gastric junctional cancers (log-
rank 480.930, γ 304, P<0.0001). The median survival for patients diagnosed with 
oesophageal cancer was 9 months (range 0.25-55), and this increased to18 months 
(range 3-55) for patients undergoing oesophagectomy.  For patients who underwent 
oesophagectomy, there was a correlation between greater deprivation and shorter 
median survival (log-rank 325.504, γ 97, P<0.0001). When analysed by quintile, the 
median survival after oesophagectomy for patients in the three most deprived 
quintiles (1-3) was 16 months (range 3-46) compared with 23 months (range 5-55) 
for patients in the two least deprived quintiles (4-5).  
For the 81 patients with oesophageal cancer treated with dCRT the median duration 
of survival was 18 months, and again there was a strong correlation between 
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residing in a deprived geographical area and shorter duration of survival (log-rank 
241.828, γ 69, P<0.0001). 
The median survival for patients diagnosed with gastric cancer was 7 months (range 
0.25-58), and this increased to 22 months (range 1-58) for patients undergoing 
gastrectomy. There was a strong correlation between duration of survival and IMD 
for all patients diagnosed with gastric cancer (log-rank 449.383, γ 247, P<0.0001). 
For patients who underwent gastrectomy, there was a correlation between greater 
deprivation and shorter median survival (log-rank 344.364, γ 89, P<0.0001). When 
analysed by quintile, the median survival after sub- or total-gastrectomy for patients 
in the three most deprived quintiles (1-3) was 24 months (range 1-64) compared with 
27 months (range 3-57) for patients in the two least deprived quintiles (4-5). 
2.4.7 Univariate analysis 
A univariate analysis of the factors influencing survival is shown in Table 3.   
2.4.8 Multivariate analysis 
Factors found to be associated with survival at the P<0.10 level on univariate 
analysis (age, IMD rank, HD rank, pre-operative rTNM stage, histopathology and 
radical treatment intent) were entered into a multivariate analysis using Cox’s 
proportional hazards model, Table 4.  
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2.5 Discussion 
This is the largest study of the effect of deprivation on outcomes in patients 
diagnosed with UGI cancer including almost 1200 patients over a four-year period. 
The principal findings were that both IMD and HD were associated with adverse 
outcomes for patients diagnosed with UGI cancer, and overall deprivation was 
associated with duration of survival. Despite developing disease at a younger age, 
being of similar stage of disease at diagnosis, and being offered similar treatment 
protocols, patients residing in the most deprived geographical areas were more likely 
to have significantly shorter median duration of survival than patients in the least 
deprived geographical areas. No differences were found in the proportion of patients 
receiving treatment with curative intent related to deprivation quintile, and similar 
proportions of patients from each quintile were offered surgery, definitive 
chemoradiotherapy and palliative care. Despite equal proportions of patients from 
more deprived backgrounds meeting mandatory performance status criteria for 
surgery, survival was significantly shorter than for patients from less deprived 
backgrounds. 
This study has a number of limitations. Deprivation exists in a number of forms and 
this multimodal complexity makes quantification challenging. Important discrepancies 
in outcome and duration of survival between UGI cancer patients from different 
socio-economic backgrounds were identified, but no explanation emerged as to why 
this should be so. This study used deprivation scores measured at the area level, i.e. 
each individual was given a score based on the degree of deprivation of their local 
community. The use of such area-based deprivation scores, as opposed to 
individual-based scores, calculated on individuals’ incomes or occupations, does 
introduce potential bias, given that it is unlikely that all residents of a specific 
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postcode will have the attributes of that community (the ecological fallacy) (Morgan 
et al. 2007). There is however a clear distinction between poverty (insufficient 
financial resources) and deprivation (insufficient multiple resources, including 
financial). IMDs are an accurate measure of true deprivation, taking into account 
poverty, housing, access to services, health and physical environment. Survival was 
calculated using all-cause mortality and it is likely that some patients will have died of 
causes other than progressive or recurrent oesophageal or gastric cancer. This is of 
particular relevance when considering deprivation, as it is acknowledged that 
patients from more deprived areas have a higher proportion of many chronic 
diseases, and their mortality is therefore higher than that of patients from more 
socio-economically advantaged areas. This latter point is, however, controversial as 
it has previously been reported that disease-specific mortality provides the most 
accurate measure of survival when no information regarding co-morbidity is available 
(Kravdal 2002). Certainly other investigators have reported that the assignment of 
cancer as a cause of death may be influenced by deprivation (Brewster et al. 2000), 
and it is therefore probable that the true oesophago-gastric cancer survival rate lies 
somewhere midway between these two extremes. This was a comparative study, 
and the definition and analysis of subgroups within a study may lead to bias, while 
comparisons of groups may prove to be not statistically significant simply because 
the study has insufficient power to demonstrate real differences. The use of quintiles 
(as opposed to quartiles or deciles, for example) was arbitrary, and it is not clear 
from the results presented here whether there is an analogue correlation between 
deprivation and outcome or whether the effect is binary, with a critical level of 
deprivation above which adverse outcomes become more likely.  
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The strengths of the study are that prospectively collected data for unselected 
consecutive patients from a well-defined geographical area were used, a significant 
proportion of whom reside in areas shown to be amongst the most deprived in the 
United Kingdom.  Access to the IMDs for over 99.5% of all the patients adds further 
strength. The prognostic data are especially robust, with over 83% of patients 
followed up for at least 24 months or until death. All patients were managed by a 
specialist MDT whose results are well audited and can stand up to international 
scrutiny (Stephens et al. 2006). Furthermore, the accuracy of the survival data is 
especially robust, as the dates for death were confirmed by the Office for National 
Statistics and outcomes have also correlated with independent formal analysis by 
Welsh Assembly Government healthcare statisticians. 
The most important prognostic factor in patients diagnosed with oesophageal or 
gastric cancer has, by tradition, been the stage of disease at diagnosis (Allum et al. 
2002). This study however, failed to demonstrate any correlation between 
deprivation and the perceived radiological tumour stage at diagnosis. The study did 
find that for all patients treated, and particularly those who had undergone surgery, 
those from least deprived geographic areas had longer median durations of survival. 
Similar proportions of the more deprived patients progressed to surgery and this 
could potentially be explained by a more focused input from allied healthcare 
professionals, dieticians and physiotherapists in particular, to optimise pre-operative 
performance in patients from more deprived geographical areas who tend to have 
poorer health and increased rates of cardio-respiratory related diseases (Carstairs 
1995; Brown et al. 2001). The findings contrast with a previous study which reported 
no association between duration of survival after oesophagectomy for cancer and 
deprivation (Morgan et al. 2007), but were in keeping with Stephens et al who 
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reported deprivation was associated with shorter duration of survival following 
gastrectomy for cancer (Stephens et al. 2005). Both of these reports utilised an 
earlier more embryonic version of the Wales IMD. 
2.6 Conclusion 
In conclusion, the Acheson report highlighted the need for action across the whole of 
society to address the deep-seated inequalities in our health (Dept of Health 1998). 
The UK Government responded by pledging a commitment to this end, inviting the 
independent Scientific Reference Group on Health Inequalities to oversee 
implementation and assess outcomes (Dept of Health 2007).  In the subsequent 
decade, life expectancy for males and females living in the 70 local authority areas 
with the worst health and deprivation indicators in England have increased by 2.9 
and 1.9 years respectively, compared with 3.1 and 2.1 years for the population as a 
whole. This highlights the point that although the health of society’s most deprived 
has improved, the gap between society’s most and least deprived has failed to 
narrow (Dept of Health 2007; Dept of Health 2009) and further research and effort to 
address these health care and deprivation related inequalities is warranted.  
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Table 2.1 Demographic details of patients related to deprivation quintile 
 
 
Deprivation 
Quintile 
 
Median IMD Rank 
 
Range 
 
Median HD Rank 
 
Range 
 
Median Age 
 
Gender (M:F) 
 
Histology  
 
    ACA 
    SCC 
    Undifferentiated 
    HGD 
 
Tumour Site 
 
Oesophageal 
Gastric 
 
Surgery 
     dCRT 
     EMR 
     Palliative 
 
1 
 
 
135 
 
2-264 
 
134 
 
1-283 
 
72 (22-94) 
 
148:88 
 
 
 
182 
32 
11 
11 
 
 
 
138 
98 
 
37 
21 
2 
176 
 
2 
 
 
407 
 
265-577 
 
400 
 
286-561 
 
72 (36-95) 
 
159:77 
 
 
 
185 
38 
10 
3 
 
 
 
136 
100 
 
50 
12 
3 
171 
 
3 
 
 
763 
 
553-972 
 
747 
 
563-911 
 
73 (24-94) 
 
169:67 
 
 
 
179 
41 
12 
4 
 
 
 
145 
91 
 
46 
20 
2 
168 
 
4 
 
 
1274 
 
978-1558 
 
1134 
 
911-1431 
 
71 (31-94) 
 
151:85 
 
 
 
179 
50 
3 
4 
 
 
 
131 
105 
 
50 
15 
7 
164 
 
5 
 
 
1744 
 
1489-1896 
 
1712 
 
1431-1895 
 
74 (42-97) 
 
152:84 
 
 
 
175 
45 
10 
6 
 
 
 
145 
91 
 
46 
13 
4 
173 
 
Figures are numbers of patients 
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Table 2.2 Details of the patients undergoing surgery 
 
 
 
 
        
 
Deprivation 
Quintile 
 
No. of pts (%) 
 
Median age 
 
Gender M:F 
 
Histopathology 
 
     ACA 
     SCC 
     HGD 
 
Site of Tumour 
 
Oesophageal 
Junctional 
Gastric 
 
Overall Stage 
 
HGD 
I 
II 
III 
IV 
 
Operation 
 
TTO 
THO 
Gastrectomy 
Subtotal Gastrx 
Oes-Gastrx 
Emergency Op 
Open & Close 
CRM +ve (%) 
 
Complications 
 
Morbidity CD≥3 
Mortality 
 
 
1 
 
37 (16) 
 
67 
 
24:13 
 
 
 
34 
1 
2 
 
 
 
15 
5 
17 
 
 
 
2 
6 
10 
15 
2 
 
 
 
6 
6 
10 
6 
1 
3 
5 
5 (13) 
 
 
 
6 (16) 
1 
 
 
2 
 
50 (21) 
 
64 
 
41:9 
 
 
 
49 
1 
0 
 
 
 
22 
8 
20 
 
 
 
0 
16 
9 
19 
5 
 
 
 
3 
12 
6 
13 
3 
4 
9 
6 (12) 
 
 
 
2 (4) 
   0 
 
 
3 
 
46(19) 
 
65 
 
36:10 
 
 
 
41 
4 
1 
 
 
 
19 
8 
19 
 
 
 
0 
9 
21 
14 
1 
 
 
 
8 
8 
11 
9 
2 
3 
5 
7 (15) 
 
 
 
10 (21) 
3 
 
 
4 
 
50 (21) 
 
67 
 
38:12 
 
 
 
45 
5 
0 
 
 
 
23 
9 
18 
 
 
 
0 
14 
10 
25 
1 
 
 
 
13 
8 
7 
12 
2 
2 
6 
11 (22) 
 
 
 
8 (16) 
0 
 
 
5 
 
46(19) 
 
66 
 
35:11 
 
 
 
44 
2 
0 
 
 
 
19 
14 
13 
 
 
 
1 
14 
16 
14 
1 
 
 
 
12 
12 
7 
9 
2 
1 
3 
13 (28) 
 
 
 
  3(7) 
    0 
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Table 2.3 Univariate analysis of factors associated with duration of survival 
 
 
 
Factor 
 
Log rank 
 
DF 
 
p-value 
 
 
Cancer site 
 
4.852 
 
1 
 
p=0.028 
 
 
Age 
 
178.628 
 
67 
 
p<0.0001 
 
 
rTNM 
 
315.129 
 
4 
 
p<0.0001 
 
 
Histology 
 
44.186 
 
3 
 
p<0.0001 
 
 
Radical Rx Intent 
 
367.524 
 
1 
 
p<0.0001 
 
 
SED Rank 
 
1586.772 
 
616 
 
p<0.0001 
 
 
HD Rank 
 
1586.772 
 
616 
 
p<0.0001 
 
 
Table 2.4 Multivariate analysis of factors associated with duration of survival 
 
 
 
Factor 
 
HR 
 
CI (95%) 
 
p-value 
 
 
Age 
 
1.021 
 
1.014-1.028 
 
p<0.0001 
 
 
Curative Rx intent 
 
0.338 
 
0.274-0.418 
 
p<0.0001 
 
 
rTNM Stage 
 
1.559 
 
1.427-1.704 
 
p<0.0001 
 
 
IMD 
 
1.000 
 
1.000-1.000 
 
p=0.084 
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Figure 2.1 2 year survival related to IMD quintile 
 
 
 
 
 
 
 
 
 
 
 
 
 
Log Rank 1586.772, γ 616, P<0.0001 
Least deprived quintile 
Most deprived quintile 
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Chapter 3 
Prognostic significance of diagnostic delay and deprivation in the 
management of upper gastrointestinal cancer 
3.1 Summary 
The aim of this study was to examine the time taken to diagnose upper 
gastrointestinal (UGI) cancer, identify sources of delay, and assess it`s prognostic 
significance. 
This was a prospective study of 150 consecutive upper GI cancer patients (median 
age 70 years, 96 males, 102 oesophageal and 48 gastric cancers respectively) 
presenting to a UK cancer network. Outcome measures were times from onset of 
symptoms to histological diagnosis, radiological-staging steps, decision to treatment, 
and whether potentially curative therapy was possible. Deprivation scores were 
obtained from the Welsh Indices of Multiple Deprivation (WIMD).    
Total delay consisted of the following components: patient delay [median 12 (1-104) 
weeks, 76%]; practitioner delay [median 1 day (range 1 day to 78 weeks), 1%] and 
hospital delay [median 25 days (1-262), 23%]. Overall median delay from onset of 
symptoms to diagnosis was 15.5 (1-142) weeks, and to decision to treat 18 (3-143) 
weeks. On multivariate analysis the factors influencing patient delay were gender 
(HR 1.463, 95% CI 1.038-2.063, p=0.030) and overall deprivation rank (HR 1.000, 
95% CI 1.000-1.001, p=0.005). Urgent Suspected Cancer (USC) referrals (open 
access endoscopy) consisted of 94 patients (63%) and were more likely to receive 
curative treatment (43%) than the 56 patients (37%) referred via Non Urgent 
Suspected Cancer (NUSC) pathways (25%, p=0.017). For USC patients the median 
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delay from receipt of GP referral to the date treatment started was 85 (1-526) days, 
with 36% of patients starting treatment within 62 days (median delay 15 days). In 
contrast, for non-USC patients the median delay from decision to treat to treatment 
commencing was 1 (1-253) day, with 91% (51/56) within 31 days. Regarding USC 
patients, 18 (24.7%) started treatment within the recommended 62 day guideline 
from time of receipt of referral, and for non-USC patients 51 (91.1%) had 
commenced treatment within 31 days. Survival was significantly related to overall 
delay (R=0.210, p=0.010), whereby patients with the shortest delays survived for a 
median 6 (0.25 to 30) months compared with patients with the longest delays who 
survived for a median 12.5 (0.5 to 32) months. 
In conclusion patient delay accounted for over three quarters of total delay, and 
deprivation was an important and independent factor in this regard. Improved public 
awareness and doctor education, lower thresholds for referral in deprived 
geographical areas, and streamlined diagnostic pathways are required if earlier 
diagnosis of UGI cancer is to be achieved. 
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3.2 Introduction 
The most important prognostic factor in patients diagnosed with oesophageal or 
gastric cancer is the stage of disease at presentation, yet despite advances in 
information technology and therapies incurable metastatic disease is still diagnosed 
in as many as 50% of patients at first presentation (Allum et al. 2002). In the 
absence of a national UK screening programme, and given that tumour doubling 
time can be as little as 2 months for advanced gastric cancer (Kohli et al. 1981; 
Haruma et al. 1988) and less than 7 months for oesophageal cancer (Nabeya et al. 
1990), avoidable delay may potentially allow tumours to upstage significantly.  
British Society of Gastroenterology (BSG) guidelines recommend that all patients 
over 55 years of age with recent onset dyspepsia, and all patients with alarm 
symptoms suggestive of UGI cancer irrespective of age, should be referred for rapid 
access endoscopy and biopsy (Allum et al. 2011). Moreover, the UK Department of 
Health has specified that these urgent investigations be performed within two weeks 
of referral (HMSO 2011). Nevertheless, the potential for delay along the patient’s 
journey are many, and delay may arise at any of three junctures from the initial onset 
of symptoms to diagnosis; the interval between first noticing symptoms and first 
consulting a doctor (patient delay); the interval between primary consultation and the 
subsequent time taken for referral for further investigations (practitioner delay); and 
finally the time between receipt of referral and diagnosis (hospital delay) (Nichols et 
al. 1981).  
Deprivation is a broad concept which includes limited access to the opportunities and 
resources which society might expect such as good health, a clean and safe living 
environment, and protection from crime. Eight types of deprivation, or domains, have 
67 
 
been described, including; employment, income, education, health, community, 
geographical access to services, housing, and physical environment (Welsh 
Assembly Government 2011). Multiple deprivation refers to the different types that 
might occur, and represents a far more profound notion than poverty alone. 
According to the Welsh Government Cancer Delivery Plan Annual Report (2014) 
considerable differences remain in cancer incidence, mortality and survival between 
the least and most deprived geographical areas of the country whereby there is a 
21% higher incidence in the most deprived areas compared with the least. 
Furthermore, one year survival rate is 17% lower in the most deprived areas 
compared with the least deprived areas, and five year survival difference is even 
greater, with 28% fewer patients in the most deprived areas surviving to 5 years 
compared with patients in the least deprived areas (Welsh Assembly Government 
2014). 
Staging protocols for oesophageal cancer are now complex including endoscopy, 
CT, PET/CT and Endoscopic Ultrasonography (EUS), all of which carry their own 
potential for further delay. As prognosis for patients diagnosed with UGI cancer is 
often poor, the potential benefit from understanding and addressing reversible 
factors is substantial. The aim of this study is to identify the source and magnitude of 
such delays, determine the prognostic significance, and examine whether delays are 
related to deprivation. 
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3.3 Material and Methods 
Data was collected on 150 consecutive patients [median age 70 years (range 26 to 
95), 96 male, 54 female, 102 oesophageal, 48 gastric cancer, 125 adenocarcinoma 
(ACA), 25 squamous cell carcinoma (SCC)], diagnosed between 1st August 2012 
and 31st July 2013 within 2 South East Wales Health Boards (Aneurin Bevan and 
Cardiff and Vale) . All patients were managed by the South East Wales UGI Cancer 
network multidisciplinary team (MDT).  
3.3.1 Time Intervals 
The time interval (weeks) between the patient first noticing symptoms and presenting 
to their general practitioner (GP) was recorded according to the patient’s personal 
recollection of events and cross-referenced with the GP urgent suspected cancer 
(USC) referral letter. For emergency admissions the delay between first noticing a 
symptom and presentation to hospital was recorded.  Practitioner delays (days) were 
recorded from the Welsh National Cancer Network Information System (CANISC) 
database and patient notes.  Hospital delays were also recorded contemporaneously 
from CANISC. For hospital delays, intervals were recorded between date of GP 
referral to the date of upper gastrointestinal endoscopy (OGD), to date of CT (days), 
from date of OGD to CT (days), from CT to EUS (weeks), from CT to PET/CT 
(weeks), from referral to diagnosis (days), from referral to the decision to treat date 
at the regional MDT (weeks), and from the decision to treat date to the 
commencement of treatment (weeks). The overall delay between initial onset of 
symptoms and the date a decision to treat was made was also recorded. Date of 
diagnosis was the day on which a histological diagnosis of malignancy was 
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confirmed. In the case of patients who did not undergo OGD date of diagnosis was 
recorded as the day the patient underwent radiological imaging. 
3.3.2 Deprivation rankings 
Deprivation rankings were designated for each patient using the Welsh Index of 
Multiple Deprivation (WIMD) 2011, (Welsh Assembly Government 2011). This index 
gives the official measure of multiple deprivation for every postcode in Wales and is 
based on the eight aforementioned forms of deprivation including employment, 
income, education, health, community, geographical access to services, housing, 
and physical environment. The country is divided into 1,896 areas of approximately 
1,500 people with the most deprived geographical area ranked 1 and the least 
deprived area ranked 1,896. The WIMD for all areas was also sub-classified into 
equally sized socio-economic quintiles; the most deprived group was labelled quintile 
1, and the least deprived quintile 5.  Health deprivation (HD) was also examined, the 
indicators for which are cancer incidence, all-cause death rate, percentage of live 
single births <2.5kg, and the number of inhabitants with limiting long-term illness per 
100,000 of the population (Welsh Assembly Government 2011). HD was similarly 
sub-classified into equally sized quintiles. 
3.3.3 Staging Investigations 
Patients deemed to have potentially curable tumours underwent diagnostic 
gastroscopy with histopathological confirmation of oesophageal or gastric cancer 
and computed tomography (CT) of the thorax and upper abdomen. Patients selected 
for radical treatment also underwent EUS, CT Positron Emission Tomography 
(PET/CT) and laparoscopy, if appropriate. Tumours were staged according to the 
unified TNM classification of UGI cancer, edition 7 (Edge et al. 2010). 
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3.3.4 Multidisciplinary management 
Patients were initially discussed at one of three local multi-disciplinary team (MDT) 
meetings and if deemed potentially curative they were then discussed at the regional 
South East Wales UGI MDT meeting. Patients were selected for appropriate radical 
treatment based on histopathological stage, co-morbidity, the technical feasibility of 
surgery and patient choice according to an algorithm described previously (Stephens 
et al. 2006). Patients unsuitable or who declined radical therapy were offered 
specialist palliative care.  
3.3.5 Statistical Analysis 
Statistical analysis appropriate for non-parametric data was used. Grouped data 
were presented as median (range), and quintiles were grouped to allow Cox 
regression analysis. Bivariate correlations were calculated using Spearman`s 
correlation test. Differences were deemed statistically significant when p<0.05. Data 
analysis was carried out with the Statistical Package for Social Sciences (SPSS) 
version 20 package (IBM Corporation, New York). 
 
 
 
 
 
 
 
71 
 
3.4 Results 
3.4.1 Patient Delay 
The median time interval between patients first experiencing symptoms and initial 
presentation to a medical practitioner was 12 (1-104) weeks and accounted for 76% 
of the delay from initial onset of symptoms until the decision to treat date. Patient 
delay correlated with gender [females 13 (2-104) weeks compared with males 8 (1-
78) weeks (R=-0.179, p=0.030)], level of overall deprivation (R=-0.214, p=0.009), 
and health deprivation (R=-0.214, p=0.009). When analysed by quintile, the median 
delay for patients in the most deprived quintile was 13 (2-78) weeks compared with 8 
(1-26) weeks for those in the least deprived quintile (R=-0.210, p=0.010). With 
regard to HD, the median delay for patients in the most deprived HD quintile was 15 
(4-78) weeks compared with 8 (1-26) weeks for those in the least deprived quintile 
(R=-0.210, p=0.010).  
Patients with oesophageal cancer had a median delay of 9 (1-78) weeks and 
patients with gastric cancer 13 (1-104) weeks (R=0.041, p=0.620). No correlation 
was found between longer patient delays and advanced radiological (r)TNM staging 
(R=-0.063, p=0.477) or with radiologically defined metastatic disease (R=0.058, 
p=0.509). For patients who underwent radiological staging, stage I disease was 
diagnosed in 11%, stage II in 17%, stage III in 27% and stage IV in 45%. 
3.4.2 Univariate analysis of factors associated with length of patient delay 
The factors associated with patient delay are shown in Table 2.   
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3.4.3 Multivariate analysis of factors associated with length of patient delay 
Factors found to be associated with patient delay (p<0.10) on univariate analysis 
were entered into a multivariate analysis using Cox’s proportional hazards model 
shown in Table 3. Gender (HR 1.463, 95% CI 1.038-2.063, p=0.030) and overall 
deprivation rank (HR 1.000, 95% CI 1.000-1.001, p=0.005) were found to be 
independently associated with patient delay. 
3.4.4 Practitioner Delay 
The median delay between a patient consulting their GP and referral for further 
investigation was 1 day (range 1 day to 18 months) and accounted for 1.25% of the 
total delay from the onset of symptoms to the decision to treat date. 
Ninety four patients (63%) were referred via the Urgent Suspected Cancer (USC) 
pathway or open access gastroscopy pathway, with the remaining 56 patients (37%) 
admitted to hospital with emergency complications of their tumours. Patients referred 
via USC pathways had a median 27 day delay (1-262) between the time of GP 
referral and diagnosis. There was an inverse correlation between age and USC 
referral (R=-0.233, p=0.004), whereby all patients younger than 50 years were 
referred via the USC route compared with 11 patients (39.3%) aged 80 years or 
older (R=-.225, p=0.006). Forty-four percent of the younger cohort were offered 
curative treatment compared with 14.3% of the older cohort (R=-0.277, p=0.001). 
There was a strong correlation between referral via USC pathway and the likelihood 
of potentially curative treatment (R=0.194, p=0.017), with 43% of USC patients 
offered treatment with curative intent compared with 25% of patients referred via 
non-USC routes. There was no correlation between gender and USC endoscopy 
referrals with 72.3% of female and 60% of male patients referred by their GPs via 
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this route (R=-0.091, p=0.269). For USC patients median delay from receipt of GP 
referral to date treatment started was 85 (1-526) days. Thirty four patients (36.2%) 
started treatment within 62 days and the median delay for this cohort was 15 (1-59) 
days. For the remaining 60 patients (63.8%), the median delay was 119 (64-526) 
days. Among non-USC patients (n=56), median delay from the decision to treat date 
was made to treatment was 1 (1-253) days, and 51 patients (91.1%) were treated 
within 31 days. For the remaining 5 patients median delay was 176 (53-253) days.  
3.4.5 Hospital Delay 
Median delay between GP referral and histological diagnosis was 25 (1-262) days 
and accounted for 23% of the total delay experienced by the patient.  
For patients undergoing surgery the median delay between diagnosis and surgery 
was 23 (2-46) weeks. Oesophageal cancer patients waited a median 25 (8-46) 
weeks compared with gastric cancer patients who had a median delay of 8 (4-29) 
weeks (R=-0.537, p=0.003). A positive correlation was observed between HD and 
delay to surgery with patients in the most deprived quintile waiting a median 25 (8-
46) weeks compared with patients in the least deprived quintile who waited 13 (4.0-
31) weeks (R=-0.401, p=0.038). No correlation was observed between the duration 
of patient delay and subsequent operability (open and close surgery, R=0.088, 
p=0.684), post-operative morbidity (R=0.180, p=0.474), post-operative mortality 
(R=0.051, p=0.840), length of hospital stay (R=0.157, p=0.535), pT (R=-0.089, 
p=0.724), pN (R=-0.012, p=0.963) or pM stage (R=-0.393, p=0.441). 
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3.4.6 Univariate analysis of factors associated with length of total delay 
The factors associated with length of total delay are shown in Table 4 
3.4.7 Multivariate analysis of factors associated with length of total delay 
Factors found to be associated with length of total delay (p<0.10) on univariate 
analysis were also entered into a multivariate analysis using Cox’s proportional 
hazards model shown in Table 5. Length of patient delay (HR 0.924, 95% CI 0.896-
0.953, p<0.0001) and urgent suspected cancer (USC) referrals (HR 0.374, 95% CI 
0.165-0.849, p=0.019) were found to be independently associated with total delay. 
3.4.8 Survival  
Median survival for all patients was 10 (0.25 to 32) months. There was no correlation 
between survival and length of patient delay (R=0.094, p=0.251), with survival similar 
irrespective of the delay (quintiles 1 and 5) at 9.5 (0.25 to 30) and 9.5 (1 to 32) 
months respectively. Survival did however correlate with overall delay (R=0.210, 
p=0.010), whereby patients with the shortest overall delay (quintile 1) survived for a 
median 6 (0.25 to 30) months compared with patients with the longest overall delay 
who survived for a median 12.5 (0.5 to 32) months. 
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3.5 Discussion 
The principal findings of this study were that delays in the diagnosis and treatment of 
UGI cancer remain common, on average approaching four months, little better than 
the 17 weeks described in a similar study in Leeds, UK some 20 years ago (Martin et 
al. 1997). In contrast to the above report however, where practitioner and hospital 
delay accounted for the majority, delay on the part of the patient was responsible for 
over 75% of the time interval between initial onset of symptoms and diagnosis. 
Deprivation and female gender were significantly and independently associated with 
longer patient delays, with females and patients residing in the most deprived 
geographical areas waiting a median of 5 weeks longer before seeking medical 
advice when compared with males and patients residing in the least deprived areas. 
Almost two thirds of patients were referred via the open access urgent suspected 
cancer (USC) endoscopy route, which was associated with younger age, and a 
higher likelihood of potentially curative treatment. The study also found that those 
patients with the shortest overall delay time subsequently had the shortest survival 
time, and on review these patients were, for the majority, emergency admissions 
with previously undiagnosed stage IV disease.   
Several factors have been implicated and reported to be associated with UGI cancer 
diagnostic delay. Traditionally, with regard to patient delay, the perceived 
significance of symptoms, the presence of pain or bleeding, and multiple symptoms 
all influence delay (MacDonald et al. 2006). Pain has been equivocally reported to be 
associated with both an apparent decreased (Grannell et al. 2001; Mariscal et al. 
2001) and increased delay (Look et al. 2003), and weight loss has also been 
reported to be associated with increased delay (Haugstvedt et al. 1991). Factors 
influencing practitioner delay include initial misdiagnosis of common symptoms and 
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the blind prescription of treatments such as acid suppression for presumed benign 
conditions in patients subsequently diagnosed with UGI cancer (MacDonald et al. 
2006). The influence of deprivation is controversial, with a report by Porta suggesting 
that lower socio-economic status was associated with increased delay (Porta et al. 
1996), yet Mikulin reported that  patients from lower socio-economic groups, once 
having presented to their GPs, experienced shorter referral times (Mikulin et al. 
1987). Other factors found to reduce practitioner delay include availability of a rapid 
access endoscopy service (Martin et al. 1997; Manes et al. 2002), the introduction of 
Department of Health cancer referral guidelines (Irving et al. 2002), male gender 
(Zilling et al. 1990), and older age (Mikulin et al. 1987).   
The study has a number of potential limitations. The length of patient delay was a 
subjective recollection on the part of the patient or their relatives without objective 
corroboration. Deprivation scores were measured at the area level, i.e. each 
individual was given a score based on the degree of deprivation of their local 
community. Area-based deprivation scores, as opposed to individual-based scores, 
calculated on individuals’ incomes or occupations, risks the introduction of potential 
bias, given that it is unlikely that all residents of a specific postcode will have the 
attributes of that community (the ecological fallacy) (Morgan et al. 2007). This was a 
comparative study, and the definition and analysis of sub-groups within a study may 
lead to bias, while comparisons of groups may prove to be not statistically significant 
simply because the study has insufficient power to demonstrate real differences. The 
use of quintiles was arbitrary. In contrast the study has several strengths in that data 
was prospectively and consecutively collected for unselected patients from a well-
defined geographical area, a large proportion of whom reside in areas shown to be 
amongst the most deprived in the United Kingdom. All patients were managed by a 
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specialist MDT whose clinical outcomes and results are well audited and can stand 
up to international scrutiny (Stephens et al. 2006). All dates were initially recorded 
according to the patient’s recollection but were then cross referenced and verified 
with the patient’s notes, the electronic clinical portal and CANISC. This is the first 
study to correlate diagnostic delay with government designed socio-economic (SED) 
and health deprivation (HD) ranking systems, and access to the SED and HD rank 
for all patients adds further strength. The findings of an association between greater 
level of deprivation and increased patient delay are in keeping with those of Porta 
(Porta et al. 1996). Regarding other patient demographic factors, the findings are in 
keeping with previous reports which did not find any association between patient 
delay and age (Mariscal et al. 2001), but contradict further studies which reported 
little evidence of any association between time to presentation and gender 
(Macdonald et al. 2006). The principal factor influencing contemporary practitioner 
delay in South East Wales appeared to be initial misdiagnosis on first presentation, a 
finding supported by Rothwell who reported delays in referral particularly for young 
female patients who were instead being blindly treated with acid suppression for a 
presumed benign condition (Rothwell et al. 1987). This finding was further supported 
by a report by Bramble (Bramble et al. 2000). Furthermore this study supports the 
findings of Manes who reported patients experienced less delay in referral where a 
rapid access service was available (Manes et al. 2002). The median delay between 
GP referral and OGD was 25 days (1 day- 37 weeks), falling short of the UK 
Department of Health recommendation that urgent OGD be performed within 2 
weeks of referral (Dept of Health 2011). Indeed only a quarter of USC referrals 
(25.7%) underwent OGD within the 14 day Department of Health cancer referral 
guidelines. Previous work has reported deprived patients were less likely to accept 
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an invitation to be screened for colorectal cancer (Whynes et al. 2003), but this was 
not apparent in the current study in that no reluctance was evident on the part of the 
most deprived patients to undergo OGD. This study found that patient delay did not 
influence survival, patients with the shortest and longest patient delay times had 
similar median survival times of 9 and 9.5 months respectively. Overall delay time 
was however significantly associated with duration of survival, patients with the 
shortest overall delay survived a median 6 months compared with 12.5 months for 
patients with longest overall delay. The former patients were however, mostly 
emergency admissions with complications of their tumours who were treated 
palliatively and did not undergo extensive radiological investigation involving EUS 
and PET/CT scans or staging laparoscopies. 
Previous reports have suggested that patient referral and hospital assessment be 
expedited in an attempt to reduce delays in diagnosis and treatment in UGI cancer 
(Martin et al. 1997). This is of particular clinical significance in UGI cancer given a 
potentially short tumour doubling time and associated poorer prognosis. There has 
been significant research performed in this arena and specific guidelines issued 
recommending that primary healthcare professionals should take part in education, 
peer review and other activities to improve the quality of clinical consulting, 
reasoning and diagnostic skills (The Royal College of Physicians1997). Yet the 
findings of this study suggest that the majority of diagnostic delay was accounted for 
by the patients rather than individual practitioners or hospital services. Indeed, 
previous UK population surveys have shown widespread lack of awareness of 
cancer symptoms (Linsell et al. 2008; Robb et al. 2009), and such awareness is 
poorer among lower socio-economic strata (Robb et al. 2009). A further Office for 
National Statistics survey reported respondents were able to name just two cancer 
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symptoms or signs with the commonest perceived sign of mischief being the 
presence of an abnormal lump, but fewer than 32% could name any other symptom 
and 9% knew of none (Cancer Research UK 2010).  
3.6 Conclusion 
In conclusion, this study has shown that long delays remain common in the 
diagnosis and treatment of upper GI cancer, and these delays are strongly 
associated with deprivation and are therefore likely associated with lack of 
awareness and poor education. In order to address this lack of understanding, the 
Cancer Reform Strategy, published in 2007, launched the National Awareness and 
Early Diagnosis Initiative (NAEDI), a partnership between the Department of Health 
and Cancer Research UK. The role of NAEDI is to help raise public awareness of 
cancer signs and symptoms, and reverse the trend towards the later diagnosis seen 
in Great Britain than in other countries with comparable health care systems. 
Previous campaigns to raise public awareness of cancer such as the UK National 
Bowel Cancer Awareness Campaign, the US National Breast Cancer Awareness 
Month and the UK National Lung Cancer Awareness campaign each significantly 
raised the profile of these specific conditions and led to increased public awareness 
of the respective red-flag signs and symptoms (Pande et al. 2014; Jacobsen et al. 
2011; Baird 2003). The next challenge for the Department of Health, organisations 
such as Cancer Research UK, and frontline clinicians is to raise public awareness of 
the potential significance of dysphagia, dyspepsia and weight loss, often the 
harbingers of UGI cancer, through efforts such as the UK Northern Oesophago 
Gastric Unit’s “Oesophagoose” annual awareness campaign.  
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Improved patient awareness and doctor education, with lower thresholds for referral 
in deprived geographical areas, allied to streamlined diagnostic pathways are 
required if earlier diagnosis of UGI cancer is to be achieved and treatment outcomes 
optimised. 
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Table 3.1 Details of diagnostic delay 
 
Delay Intervals 
 
Oesophagus 
 
Gastric 
 
All 
 
Symptoms to GP (weeks) 
 
9 (1-78) 
 
13 (1-104) 
 
12 (1-104) 
 
GP to referral (days) 
 
1 (1-5) 
 
1 (1-546) 
 
1 (1-546) 
 
Referral to OGD (days) 
 
25 (1-201) 
 
25.5 (1-262) 
 
25 (1-262) 
 
Referral to CT (days) 
 
33.5 (1-212) 
 
35.5 (1-268) 
 
34 (1-268) 
 
Symptoms to diagnosis (weeks) 
 
13 (1-64) 
 
17 (2-142) 
 
15.5(1-142) 
 
CT to EUS (weeks) 
 
4 (2-10) 
 
3 (2-4) 
 
4 (2-10) 
 
CT to PET/CT (weeks) 
 
3 (0.5-11.5) 
 
2.5 (1.5-3.5) 
 
3 (0.5-11.5) 
 
Referral to decision to treat (weeks) 
 
6 (1-33) 
 
5.5 (0.5-39) 
 
6 (0.5-39) 
 
Total delay from symptom onset  to 
decision to treat (weeks) 
 
16 (3-69) 
 
20 (3-143) 
 
18 (3-143) 
Numbers are median (range) 
 
Table 3.2 Univariate analysis of factors associated with length of patient delay 
 
 
Factor 
 
Age 
Age (per decade) 
Gender 
IMD Rank 
HD Rank 
 
Log Rank 
 
57.513 
8.883 
4.822 
416.390 
416.390 
 
DF 
 
45 
4 
1 
136 
136 
 
p-value 
 
p=0.100 
p=0.064 
p=0.028 
p<0.0001 
p<0.0001 
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Table 3.3 Multivariate analysis of factors associated with length of patient 
delay 
 
Factor 
 
Gender 
IMD Rank 
 
HR 
 
1.463 
1.000 
 
CI (95%) 
 
1.038-2.063 
1.000-1.001 
 
p-value 
 
p=0.030 
p=0.005 
 
 
Table 3.4 Univariate analysis of factors associated with length of total delay 
 
 
Factor 
 
Age 
IMD Rank 
HD Rank 
Length patient delay 
Practitioner delay 
Delay referral to OGD 
Delay referral to diagnosis 
Delay symptoms diagnosis 
USC Referral 
 
Log Rank 
 
93.935 
519.419 
519.410 
131.871 
28.656 
135.650 
133.625 
217.472 
10.626 
 
DF 
 
45 
136 
136 
20 
3 
54 
56 
51 
1 
 
p-value 
 
p<0.0001 
p<0.0001 
p<0.0001 
p<0.0001 
p<0.0001 
p<0.0001 
p<0.0001 
p<0.0001 
p=0.001 
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Table 3.5 Multivariate analysis of factors associated with length of total delay 
 
 
 
Factor 
 
Patient Delay 
USC Referral 
 
HR 
 
0.924 
0.374 
 
CI (95%) 
 
0.896-0.953 
0.165-0.849 
 
p-value 
 
p<0.0001 
p=0.019 
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Chapter 4  
Prognostic significance of body composition determined by 
Bioelectrical Impedance Analysis (BIA) in upper gastrointestinal 
cancer surgery 
 
4.1 Summary 
Malnutrition and sarcopenia are associated with higher rates of operative morbidity 
and therefore represent potentially reversible prognostic risk factors. Bioelectrical 
Impedance Analysis (BIA) is a non-invasive, easily reproducible and inexpensive 
means of accurately measuring body composition, and the aim of this study was to 
determine the prognostic value of BIA and sarcopenia in UGI cancer surgery.  
                                                                                                                    
Consecutive 125 patients [median age 66 years (24-86), 94 males, 73 oesophageal 
and 52 gastric cancers] underwent pre-operative BIA (Maltron Bioscan 920) 
assessment to measure percentage Free Fat Mass (FFM%), percentage Body Fat 
(BF%), percentage Lean Muscle Mass (LMM%), Total Body Water (TBW%), 
Intracellular and Extracellular Fluid Volume (ICV, ECV, %), and Phase Angle (PhA). 
Furthermore, the lean muscle mass for each patient was divided by their total body 
weight, the results were then split into quartiles and the quartile with the lowest lean 
muscle mass to total body weight ratio was used as a surrogate for sarcopenia. 
Primary outcome measures were operative morbidity and length of hospital stay. 
 
Pre-operatively anaerobic threshold (AT) correlated with ICV% (R=0.370, p=0.001), 
LMM% (R=0.236, p=0.042), and PhA (R=0.289, p=0.010). Surgery mortality risk (O-
POSSUM score) correlated with FFM% (R=0.247, p=0.020) and BF% (R=0.259, 
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p=0.015). Sarcopenia was associated with AT (R=0.277, p=0.017), operative 
severity (R=0.330, p=0.003), P-POSSUM morbidity (R=0.306, p=0.005), and P-
POSSUM mortality (R=0.239, p=0.031). Sarcopenia was also associated with female 
gender (R=-0.705, p<0.001), and tumours located in the distal oesophagus (R=-319, 
p=0.033). Open and close laparotomy was associated with FFM% (R=0.200, 
p=0.027), and BF% (R=-0.197, p=0.030). Post-operative morbidity (Clavien-Dindo 
≥3) was associated with ICV (R=0.265, p=0.018), TBW (R=0.269, p=0.019), and 
sarcopenia (R=0.232, p=0.045), the quartile most affected by sarcopenia showed 
almost twice the rate of Clavien-Dindo ≥3 complications compared with the quartile 
least affected (24.1% vs 13.8%). Critical care length of stay was associated with ICV 
(R=0.279, p=0.009), LMM (R=0.302, p=0.006), PhA (R=0.239, p=0.025) and 
sarcopenia (R=0.236, p=0.011). 
 
In conclusion BIA defined body composition is an important and independent 
prognostic indicator in UGI cancer. Further research is warranted to determine 
critical body composition values so that enhanced recovery programmes containing 
bespoke nutritional strategies may be developed to improve surgical outcomes. 
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4.2 Introduction 
Cachexia affects up to two-thirds of patients with cancer, and the extent of 
malnutrition is related to the site, stage and type of the tumour. It is especially 
pronounced in oesophageal and gastric cancers (Bozetti et al. 1982). It is a 
multifactorial syndrome characterised by weight loss, altered metabolism of lipids, 
protein and carbohydrates, loss of both skeletal muscle and white adipose tissue, 
and anaemia (Argiles et al. 1997). Indeed, it has been reported that cachexia is 
responsible for at least 20% of cancer-related deaths rather than the underlying 
tumour itself, and decreases the quality of life in many more patients (Ottery 1994). A 
decline in food and energy intake, coupled with elevated resting energy expenditure, 
is the fundamental physiologic derangement leading to cancer-associated weight 
loss (Kern et al. 1988). Furthermore, after a point it may not be possible to reverse 
the process even with intensive nutritional support, including total parenteral nutrition 
(Costa et al. 1980). Finally, sarcopenia describes a syndrome characterised by 
progressive generalised loss of skeletal muscle mass and strength. In 2010 the 
European Working Group on Sarcopenia published consensus guidelines on the 
definition and diagnosis of sarcopenia. Known risk factors for sarcopenia include 
increasing age and inadequate nutrition, and it can be diagnosed by low muscle 
mass measured, for example, by bioimpedence (Cruz-Jentoft et al. 2010) 
Malnutrition alters the relative fluid distribution between intra- and extracellular 
compartments whereby there is a characteristic increase in extracellular volume 
(ECV) and resultant decrease in intracellular volume (ICV). An increase in cancer-
related tumour necrosis factor (TNF) lowers both transmembrane Na+ gradients and 
muscle cell membrane potential. These changes, in combination with an increase in 
inflammatory cytokines, oxygen radicals and altered hormone homeostasis induce 
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extracellular expansion and cellular shrinkage. The resultant intracellular dehydration 
triggers proteolysis and catabolism. Previous authors report there is evidence that 
the catabolism causing these fluid shifts also governs the degree of protein wasting 
and ultimately survival (Davis et al. 2009). 
 
Upper gastrointestinal (UGI) cancer resection falls within the category of high risk 
surgery as defined by the Royal College of Surgeons of England (RCSE 2011).  Pre-
operative malnutrition is associated with higher rates of post-operative sepsis and 
morbidity (Deans et al. 2007), and is therefore a potentially reversible prognostic risk 
factor of particular relevance to patients with resectable UGI tumours. Current risk 
assessment tools for patients undergoing UGI cancer resection include the American 
Society of Anaesthesiologists (ASA) physical status classification system, Cardio-
Pulmonary Exercise (CPEX) testing and the Physiological and Operative Severity 
Score for the enUmeration of Mortality and Morbidity (POSSUM) scoring.  
 
Bioelectrical Impedance Analysis (BIA) is a non-invasive, easily reproducible and 
inexpensive means of accurately measuring total body water (TBW), ICV, ECV, fat-
free mass (FFM) and changes in the distribution between these media. Single 
frequency BIA at 50 kHz measures body resistance and reactance to an alternating 
electrical current and can also quantify body fat and lean body mass, and is 
therefore indicative of nutritional status. The Phase Angle (PhA), a further parameter 
measured by BIA, is the ratio of resistance and reactance, where resistance is a 
reflection of the intracellular fluid and electrolyte volume and reactance is a measure 
of cellular membrane integrity. A low PhA implies decreased cellular integrity or cell 
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death, a high PhA is a sign of intact and healthy cellular membranes. From these 
measurements PhA can also be considered a reliable indicator of malnutrition.  
 
More recently BIA, and in particular the PhA, has been used as a prognostic marker 
to predict survival in colorectal and pancreatic cancer (Gupta et al. 2004; Gupta et al. 
2004). The disruption to cellular membrane integrity, altered fluid balance and 
electrolyte disturbances seen in UGI cancer however has not yet been investigated. 
The aim of this study was to determine the prognostic value of BIA-derived body 
composition in UGI cancer surgery. Outcome measures were post-operative 
morbidity and length of hospital stay, particularly critical care length of stay. 
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4.3 Material and Methods 
This was a prospective study of 125 consecutive patients [median age 66 (24-86) 
years, 94 males, 73 oesophageal and 52 gastric cancers] undergoing surgery for 
histologically confirmed upper gastrointestinal cancer. Patients were treated within 
an Enhanced Recovery after Surgery (ERAS) programme by the South East Wales 
UGI cancer multi-disciplinary team from August 2011 to April 2014. Patient details 
were collected prospectively and data was cross-referenced with the oncology 
(CANISC) database. Informed consent was obtained from all patients and ethical 
approval was sought from the regional ethics committee. 
 
4.3.1 Bioelectrical Impedance Analysis 
Patients underwent multi-frequency (0.5 kHz, 50 kHz and 100 kHz) BIA assessment 
using a Maltron Bioscan 920 (Maltron International Ltd, Essex, UK). BIA was 
measured by the same clinician pre-operatively on the day of surgery and again on 
pre-planned days post-operatively. Demographic data (age, gender, ethnicity) and 
clinical data (height, weight, renal function and dependence on dialysis) were 
recorded on the Bioscan software prior to assessment. The patient was supine and 
motionless throughout the test and the right arm was held equidistant from the torso 
on each testing. Measurements taken included TBW%, ICF%, ECF%, FFM%, BF%, 
and PhA, calculated using the formula: PhA = [(arc tangent resistance / reactance) × 
(180˚/π)]. Furthermore, the lean muscle mass percentage for each patient was 
divided by their total body weight, the results were then split into quartiles and the 
quartile with the lowest LMM% to total body weight ratio was used as a surrogate for 
sarcopenia. CPEX testing was routinely performed by specialist anaesthetic 
colleagues as part of the pre-surgery work-up, and all patients had ASA, P-POSSUM 
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and O-POSSUM scores calculated. BIA parameters were also sub-divided into 
equally sized quintiles to facilitate subgroup analysis of patients and allow 
comparison across the spectrum. 
 
4.3.2 Details of Surgery 
Surgery was performed by one or a combination of seven UGI surgeons. For early 
stage oesophageal tumours (T1-2, N0), a transhiatal resection as described by 
Orringer was performed (Orringer 1984). It was also employed selectively for 
patients with more advanced adenocarcinomas of the lower third of the oesophagus 
(T3 N1), and for patients with significant associated co-morbidity (ASA grade ≥III). 
The remaining oesophageal cancer patients underwent standard subtotal 
oesophagectomy as described by Lewis and Tanner (Lewis 1946; Tanner 1947). 
Patients with gastric cancer underwent a modified radical D2 resection with extended 
lymphadenectomy but preserving the pancreas and spleen where possible. Morbidity 
included all complications occurring up to 30 days post-operatively, and 
complications were graded using the Clavien-Dindo Classification of surgical 
complications (Dindo et al. 2004).  
 
 4.3.3 Statistical Analysis 
Statistical analyses were performed using the IBM Statistical Package for Social 
Sciences (SPSS) Statistics 20 package (IBM Corporation, New York). Grouped data 
were presented as median (range). Bivariate correlations were calculated using 
Spearman`s correlation test. Differences were deemed statistically significant when 
p<0.05. Lengths of critical care and ITU stay were plotted on the life-table method of 
Kaplan and Meier (Kaplan et al. 1958). 
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4.4 Results 
One hundred and twenty five consecutive patients newly diagnosed with 
histologically confirmed UGI cancer were recruited to the study. There were 94 
males and 31 females, 73 patients had oesophageal cancer and 52 gastric cancer. 
Median age was 66 (24-86) years. Radiological TNM (rTNM) staging at presentation 
was as follows: stage I (n=36, 29%), stage II (n=37, 30%), stage III (n=49, 39%) and 
stage IV (n=3, 2%).  
 
4.4.1 Pre-Operative  
Anaerobic threshold (AT) correlated with ICV% (R=0.370, p=0.001), LMM% 
(R=0.236, p=0.042), and PhA (R=0.289, p=0.010). Surgery mortality risk (O-
POSSUM score) correlated with both FFM% (R=-0.247, p=0.020) and BF% 
(R=0.259, p=0.015).  Staging CT N stage correlated with FFM% (R=0.260, p=0.011), 
BF% (R=-0.245, p=0.016) and TBW% (R=0.358, p=0.001), while CT M stage 
correlated with FFM% (R=0.341, p=0.001), BF% (R=-0.330, p=0.001), and TBW% 
(R=0.459, p<0.0001). Sarcopenia was associated with AT (R=0.277, p=0.017), 
operative severity (R=0.330, p=0.003), P-POSSUM morbidity (R=0.306, p=0.005), 
and P-POSSUM mortality (R=0.239, p=0.031). Sarcopenia was also associated with 
female gender (R=-0.705, p<0.001), and tumours located in the distal oesophagus 
(R=-319, p=0.033).  
 
4.4.2 Peri-operative 
Open and close laparotomy was significantly associated with FFM% (R=0.200, 
p=0.027), and BF% (R=-0.197, p=0.030). Positive circumferential margins were 
associated with BF% (R=0.212, p=0.050), and the ratio of positive resected lymph 
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nodes was associated with ECV% (R=0.205, p=0.041). Post-operative morbidity 
(Clavien-Dindo ≥3) was associated with ICV (R=0.265, p=0.018), TBW (R=0.269, 
p=0.019), and sarcopenia (R=0.232, p=0.045). Critical care length of stay (CCLOS) 
was associated with ICV (R=0.279, p=0.009), LMM (R=0.302, p=0.006), PhA 
(R=0.239, p=0.025) and sarcopenia (R=0.236, p=0.011), while ITU LOS in particular 
was associated with ICV (R=0.227, p=0.034), PhA (R=0.268, p=0.012) and again 
sarcopenia (R=0.236, p=0.011). 
 
Figure 4.1 Critical care length of stay related to sarcopenia 
 
                       Chi2 7.835 DF 1 p=0.005 
 
 
Table 4.1 Post-operative complications related to sarcopenia quartiles 
  
Quartile 1 
 
Quartile 2 
 
Quartile 3 
 
Quartile 4 
 
Clavien-Dindo≥3 
 
24.1% 
 
13.8% 
 
17.2% 
 
13.8% 
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Figure 4.2 ITU length of stay related to sarcopenia 
 
                                  Chi
2 
5.301 DF 1 p=0.021 
 
 
 
Table 4.2 Median (range) lengths of stay related to sarcopenia quartiles 
 
  
Quartile 1 
 
Quartile 2 
 
Quartile 3 
 
Quartile 4 
 
LOHS 
 
13 (4-52) 
 
14 (4-30) 
 
14 (5-95) 
 
13 (3-41) 
 
CCLOS 
 
1 (0-38) 
 
1 (0-9) 
 
1 (0-28) 
 
1 (0-17) 
 
ITU LOS 
 
0 (0-38) 
 
0 (0-6) 
 
0 (0-28) 
 
0 (0-17) 
 
HDU LOS 
 
0 (0-28) 
 
1(0-5) 
 
1 (0-13) 
 
0 (0-3) 
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4.5 Discussion 
This study is the first to employ Bioelectrical Impedance Analysis to determine the 
prognostic significance of body composition in upper gastrointestinal cancer surgery 
patients. The principal findings are significant correlations between certain body 
composition measurements as determined by BIA and the rate of open and close 
laparotomy, post-operative morbidity, and critical care length of stay. Pre-operatively 
PhA, ICV, LMM and sarcopenia correlated significantly with anaerobic threshold 
levels, while FFM and BF correlated with O-POSSUM scores. Sarcopenia correlated 
with operative severity, P-POSSUM morbidity, and P-POSSUM mortality. Surgical 
complications scoring Clavien-Dindo grade 3 or above i.e. requiring surgical, 
endoscopic or radiological intervention at a minimum were strongly associated with 
ICV, TBW and sarcopenia. The PhA, ICV, LMM and sarcopenia correlated strongly 
with critical care length of stay, the two former measurements being particularly 
strongly associated with ITU length of stay.  
 
The strengths of the study are that data was collected prospectively from one 
hundred and twenty five unselected consecutive patients undergoing surgery for 
histologically confirmed upper gastrointestinal cancer. These details were also cross-
referenced with the national oncology (CANISC) database. All patients were 
managed by a specialist MDT whose results are well audited and can stand up to 
international scrutiny (Stephens et al. 2006). BIA measurements were taken by one 
of two operators in the same manner and using the same protocol at fixed pre-
operative times. The study used multi-frequency BIA which is a more accurate 
means of estimating the TBW (Martinoli et al. 2003). Furthermore, none of the 
patients were lost to follow-up. 
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The study has a number of limitations. The study population was a combination of 
both oesophageal and gastric cancer patients and analyses were conducted on the 
group as a whole with no comparisons made across the groups. With continued 
recruitment over time further testing will be undertaken to identify any potential 
differences or particular trends in the two groups. Analyses were only performed on 
those patients who were deemed potentially suitable and fit enough for surgery. 
Further investigation will also be undertaken in those patients who present with non-
resectable tumours to determine baseline measurements and thereby initiate 
specialist dietetic input tailored to their individual needs. A surrogate measurement of 
sarcopenia was used in the study but the objective assessment of sarcopenia using 
CT-measured psoas muscle density has now begun and will be incorporated into 
future studies. Finally we were unable to compare our findings to other similar 
studies involving oesophageal and gastric cancer.  
 
The study found that significant post-operative complications requiring surgical, 
radiological or endoscopic intervention were associated with sarcopenia and this was 
in keeping with Naber et al who found the risk of complications after admission to 
hospital was higher in malnourished patients (Naber et al. 1997). The study also 
found that critical care length of stay was associated with lean muscle mass and this 
is in keeping with Pichard et al who reported that fat-free mass was significantly 
associated with an increased length of hospital stay (Pichard et al. 2004). 
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4.6 Conclusion 
Upper GI cancer patients undergoing major resections must be assessed and 
provided with tailored goal-directed nutritional support in order to reduce the 
operative morbidity and mortality associated with complications, in particular 
anastomotic leak, wound dehiscence or infection. This study shows BIA defined 
body composition is an important and independent prognostic indicator in UGI 
cancer. Further research is warranted to determine critical body composition values 
so that enhanced recovery programmes containing bespoke nutritional strategies 
may be developed to improve outcomes and survival. 
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Chapter 5 
Centralisation of upper gastrointestinal cancer: does a regionalised 
service model influence patient safety, quality of care and survival?  
5.1 Summary 
The aim of this study was to determine the influence of a centralised upper 
gastrointestinal (UGI) cancer service model on post-operative morbidity and survival. 
 Prospective and contemporaneous details of 1177 consecutive UGI cancer patients 
were collected before (n=566) and after (n=611) centralisation of care. Primary 
outcome measure was survival, secondary outcome measures were rates of curative 
intent, operative morbidity, and length of hospital stay.  
Treatment with curative intent was offered to 122 (21.6%) and 181 (29.6%) patients 
before and after centralisation respectively (χ² = 10.007, DF=1, p= 0.002), with 
resectional surgery performed in 78 (81.3%) and 99 (81.1%) patients (p =0.985) pre- 
and post-centralisation. The incidence of serious post-operative morbidity (Dindo-
Clavien ≥ 3) decreased from 19 (22.3%) to 15 (12.5%) patients before and after 
centralisation (χ² =1.690, DF = 1, p= 0.194). There were significant reductions in ITU 
(p<0.0001) and critical care unit (p<0.0001) lengths of stay, with overall length of 
hospital stay reduced by 2.5 days (p= 0.008). Rate of re-admission to critical care 
decreased from 10 (29.4%) to 6 (6.3%) (χ² = 12.480, DF = 1, p<0.0001). There were 
5 (5.9%) operative deaths before and 1 (0.8%) operative death after the introduction 
of a centralised service (χ² = 3.977, DF=1, p= 0.046).  Median survival pre-
centralisation was 9 (0.25-73) months compared with 10 (0.25-49) months post-
centralisation (χ² = 175.293, DF = 87, p<0.0001). On univariate analysis of factors 
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influencing two-year survival centralisation was statistically significant (p=0.001). On 
multivariate analysis radiological TNM (rTNM) stage and open and close procedures 
were independently associated with two-year survival. 
The study demonstrated an increased proportion of patients receiving potentially 
curative treatment, fewer cancelled operations, reduced operative morbidity requiring 
intervention, reduced total length of hospital stay, and improved survival, many by 
significant margins. The study thereby clearly supports the centralisation of surgery 
for upper gastrointestinal cancer. 
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5.2 Introduction 
Centralisation of upper gastrointestinal (UGI) cancer surgery was first proposed in 
the Calman-Hine Report which recommended limiting oesophago-gastric cancer 
surgery to specialised, designated high-volume sites in order to improve peri-
operative mortality and long-term survival (Dept of Health 1995). Furthermore, in 
2001 the Improving Outcomes Guidance document recommended that these 
specialist cancer units should aim to perform at least 40 oesophagectomies and 60 
gastrectomies each year drawing patients from catchment areas with populations of 
one to two million (Dept of Health 2001). More recently the Association of Surgeons 
of Great Britain and Ireland (AUGIS) suggested the ideal unit would have four to six 
dedicated UGI surgeons each performing a minimum of 15 to 20 resections per year 
(AUGIS 2010). The process of centralisation began in 2001 and by 2013 there were 
41 specialist centres established across England and Wales. 
The rationale underpinning the introduction of a centralised service was that 
oesophageal cancer surgery, amongst the most complex surgical procedures, would 
benefit if performed in specialist high-volume centres of excellence. Historically the 
provision of UGI cancer resectional surgery was poorly organised and fragmented, 
undertaken by individual surgeons operating on very small numbers of patients, and 
was associated with a 30 day mortality rate of between 10 to 20% (Bachmann et al. 
1999; Northern and Yorkshire Cancer Registry and Information Service 1999). 
Indeed a previous report published in 2007 stated “any given surgeon would see 
relatively few cases per year, resect even fewer and outcomes were notoriously 
poor” (Siriwardena 2007). A centralised multi-disciplinary service would improve 
patient care via explicit referral protocols, appointed lead clinicians, dedicated 
radiological services, clinical nurse specialists and intensive care units with specialist 
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post-operative support. Surgery, widely regarded as the only intervention that can 
offer a cure for UGI cancer, would only be undertaken by designated members of 
specialist teams in centres performing approximately one hundred resections per 
year (Dept of Health 2001). The emphasis on a concentrated workload followed a 
seminal study in the US which reported a patient’s chances of survival increase 
substantially if operated on by a surgeon who performs the operation on a frequent 
basis (Birkmeyer et al. 2003). This finding was further supported by a meta-analysis 
which reported a survival benefit after oesophagectomy in favour of high-volume 
surgeons (Brusselaars et al. 2014). Additionally, operating on a difficult case within a 
centralised specialist unit offers the benefit of an immediate second opinion and an 
experienced consultant assistant if and when required (Morgan et al 2008).  
Since its inception however, centralisation has remained controversial and continues 
to polarise opinion. Despite having been shown to significantly improve in-hospital 
and 30 day mortality, the data regarding long-term survival remains limited and even 
contradictory in some individual studies (Gruen et al. 2009; Lagergren et al. 2013;  
Lauder et al. 2010; Markar et al. 2012; Tol et al. 2012; Wouters et al. 2012). The 
disadvantages of a centralised service can be seen from both a patient and a service 
provision perspective. For patients there is the increased distance from home and 
greater social isolation, in addition to the expenses incurred by visiting families. From 
an NHS perspective local district general hospitals are downgraded and lose their 
cancer workload with subsequent loss of surgical skills. Also, the hospitals appointed 
to provide a centralised service have to address the initial costs and increased 
infrastructure required to establish a high-volume centralised centre (Siriwardena 
2007).  
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The aim of this study was to determine the influence of a re-configured centralised 
service, allied to an enhanced recovery after surgery (ERAS) programme, when 
compared with the historical control outcomes of three local hospital trusts in the two 
years preceding centralisation. The setting was a UK regional cancer network 
serving a population of 1.4 million. 
5.3 Material and Methods 
The South East Wales cancer network encompasses three National Health Service 
Health Boards; Cardiff and Vale University Health Board (C&V UHB, catchment 
population 450,000), Aneurin Bevan Local Health Board (AB LHB, catchment 
population 600,000) and Cwm Taf Local Health Board (CT LHB, catchment 
population 325,000). Together these LHBs are responsible for six acute hospitals: 
four district general hospitals and two teaching hospitals. Before August 2010, the 
surgical care of patients with oesophago-gastric cancer was delivered by eight 
surgeons operating at four different hospital sites. An agreement was reached in 
December 2009 to re-configure and centralise the UGI surgical service on a single 
site at the University Hospital of Wales, Cardiff, with an agreed start date of 1st 
August 2010.  
The new model was based on five specialist UGI surgeons carrying out all the 
resectional surgery; three of the surgeons were based at the surgical centre and the 
other two were to operate on an in-reach basis, with a facility for joint consultant 
operating where necessary. Diagnosis and staging continued to be undertaken 
locally within each heath board, co-ordinated via three local MDT meetings, and all 
cases deemed suitable for curative treatment were subsequently discussed at a 
weekly South East Wales MDT meeting. Specific additional changes at the Royal 
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Gwent Hospital, Newport, included a two-fold increased frequency of local MDT 
meetings from fortnightly to weekly and the establishment of a dedicated UGI cancer 
out-patient clinic, serviced by one of the Cardiff-based surgeons. Integral to the new 
surgical model was the establishment of an enhanced recovery after surgery (ERAS) 
programme based on the established principles introduced in colorectal surgery 
(Basse et al. 2000). 
The oesophageal and gastric cancer caseload referred to the MDTs during the two 
years preceding the introduction of centralisation (August 2008 to July 2010) was 
compared with the following two years (August 2010 to July 2012). Pre-centralisation 
data across the three health boards was collected using a combination of a 
prospectively maintained database combined with MDT records and a retrospective 
review of all hospital records. Measures of outcome included post-operative 
morbidity and mortality, length of hospital stay and survival rate 2 years from 
diagnosis. All patients were followed up for at least 2 years or until death and no 
patients were lost to follow-up. Dates and causes of death were obtained by the 
Wales Cancer Intelligence and Surveillance Unit from the Office for National 
Statistics (ONS) thus ensuring accurate survival times for all patients.  
All patients had management plans individually tailored according to factors relating 
to both the patient and their disease. Staging was by means of computed 
tomography (CT), endoscopic ultrasound (EUS), computed tomography positron 
emission tomography (PET/CT), and staging laparoscopy as appropriate. The South 
East Wales MDT treatment algorithms for oesophageal and gastric cancer have 
been described previously (Lewis et al. 2002; Morgan et al. 2009). Operative 
morbidity was graded in accordance with the Clavien-Dindo classification system 
(Dindo et al. 2004). Particular emphasis was placed on the incidence of morbidity of 
103 
 
Clavien-Dindo grade III or higher, as this represented a complication requiring any 
combination of endoscopic, radiological or surgical intervention, in contrast with 
morbidity of lower grade requiring only pharmacological treatment. Definitive 
chemoradiotherapy was offered to patients with localised squamous cell carcinoma 
and patients with adenocarcinoma deemed unsuitable for surgery because of 
disease extent and/or medical co-morbidity. 
Grouped data were expressed as the median (range) and non-parametric statistical 
methods were used. Bivariate correlations were calculated using Spearman`s 
correlation test. Continuous data were compared using the Mann-Whitney test and 
categorical data using the chi-squared test. A non-parametric two-sample test on the 
equality of medians was carried out. This tested the null hypothesis that pre-
centralisation and post-centralisation patients were drawn from populations with the 
same median. Cumulative overall survival was calculated by the life-table method of 
Kaplan and Meier. Differences in survival between groups of patients were analysed 
using the log-rank method. Differences were deemed to be statistically significant 
when the p-value was less than 0.05. Factors found to be significantly associated 
with duration of survival on univariate analysis and with p-value <0.10 were entered 
into a multivariate analysis using Cox’s proportional hazards model.  
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5.4 Results 
A total of 1177 UGI cancer patients presented to the regional MDTs over the four-
year period, 566 (48.1%) pre- and 611 (51.9%) post-centralisation. There were 779 
males (66.2%), median age was 73 (22-97) years and 692 patients (59%) had 
oesophageal cancer (Table 1 shows demographic and treatment details).  
5.4.1 Details of Patient Treatment 
Pre-operatively there was a statistically significant increase in the proportion of rTNM 
stage IV tumours detected post-centralisation compared with pre-centralisation (37% 
vs 46%, p=0.008). Potentially curative treatment however, was still offered to 182 
(29.8%) patients after centralisation compared with 129 (22.8%) before (χ² = 7.396, 
DF = 1, p= 0.007). The rate of surgery with curative intent was similar before and 
after centralisation with 78 (81.25%) and 99 (81.2%) cases respectively (p =0.985). 
Of those patients treated surgically, 33 and 50 underwent oesophagectomy and 35 
and 49 underwent gastrectomy pre- and post-centralisation respectively. 
Cancellation rates decreased from 9 (8.7%) to 6 (5.1%) after centralisation 
(p=0.253). The rate of open and close laparotomy remained comparable at 12 
(14.1%) and 16 (13.3%) respectively (χ² = 0.314, DF = 1, p=0.575). The number of 
patients undergoing curative EMR increased from 2 to 20 before and after 
centralisation respectively (χ² = 10.309, DF = 1, p= 0.001).  
 
 
 
 
105 
 
5.4.2 Operative Morbidity and Mortality 
Data regarding short-term surgical outcomes and duration of hospital stay are 
presented in Table 2. There were 5 (5.9%) operative deaths before and 1 (0.8%) 
operative death after centralisation (χ² = 3.977, DF = 1, p= 0.046). The causes of the 
five pre-centralisation in-hospital deaths were two natural deaths 10 and 30 days 
after open and close attempted Ivor Lewis oesophagectomies, one myocardial 
infarction 2 days after a total gastrectomy, intra-abdominal sepsis after a total 
gastrectomy and a case of multi-organ failure secondary to conduit necrosis after 
trans-thoracic oesophagectomy. The death after centralisation was due to intra-
abdominal sepsis after sub-total gastrectomy. The incidence of post-operative 
morbidity (Clavien-Dindo ≥ 3) decreased from 19 (22.3%) to 15 (12.5%) patients 
before and after centralisation (χ² = 1.690, DF = 1, p= 0.094).  Anastomotic leaks 
occurred in 9 (10.5%) and 8 (6.7%) patients before and after respectively (χ² = 
0.389, DF = 1, p= 0.533).  
5.4.3 Duration of Hospital Stay 
Centralisation was associated with a significant reduction in ITU (p<0.0001) and 
critical care (p<0.0001) length of stay for all surgical patients. The overall length of 
hospital stay for surgical patients decreased by 2.5 days (p= 0.008). The rate of re-
admission to critical care significantly decreased from 10 (29.4%) to 6 (6.3%) before 
and after centralisation (χ² = 12.480, DF = 1, p<0.0001), while 30 day hospital re-
admission rates remained similar at 8 (12.7%) and 13 (11.2%) respectively (χ² = 
0.088, DF = 1, p = 0.767).   Regarding the 13 patients re-admitted post-centralisation 
(pneumonia=3, dysphagia=2, intra-abdominal collection=2, incisional hernia=1, 
wound infection=2, chyle leak =1, pancreatitis=1, urinary retention=1), one patient 
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required radiological drainage of a sub-phrenic abscess and the remaining patients 
were treated conservatively, for the most part in their referring local district general 
hospital. 
5.4.4 Survival 
The median survival for all patients was 9 (0.25-73) months, increasing to 34 (3-73) 
months for patients who underwent surgery with curative intent. For all patients 
median survival pre-centralisation was 9 (0.25-73) months compared with 10 (0.25-
49) months post-centralisation (p<0.0001). Two year survival for all patients before 
centralisation was 23% and 26% after centralisation (p=0.277). The percentage of 
patients who survived for one year after curative resectional surgery increased from 
88% pre-centralisation to 92% after centralisation (p=0.438), and the two year 
survival rate was similar at 73% for both groups respectively (p=0.959). Regarding 
patients who underwent oesophagectomy with curative intent, one year survival rate 
pre-centralisation was 90% compared with 95% post-centralisation (p=0.512). 
5.4.5 Factors Influencing Two Year Survival  
A univariate analysis of factors influencing two-year survival is shown in Table 3, 
centralisation being a statistically significant factor, (p=0.001). All factors found to be 
significant on univariate analysis were included in a multivariate analysis. A 
backward elimination stepwise regression was carried out whereupon rTNM and 
open and close procedures were found to be independently associated with two-year 
survival.  
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Figure 5.1 Kaplan-Meier survival plot related to centralisation for all patients 
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5.5 Discussion 
Since its inception the centralisation of UGI cancer care has remained a 
controversial topic of debate in several countries (Brusselaars et al. 2014). This 
study however, showed that a centralised service was able to provide potentially 
curative treatment to a significantly greater number of patients and with a reduced 
number of cancelled operations. Furthermore, for those patients who underwent 
surgery, centralisation was associated with shorter critical care and total hospital 
lengths of stay, reduced post-operative morbidity, decreased number of re-
admissions to ITU, less operative deaths and increased one year survival rate.  
The strengths of the current study are that with a study population approaching 
nearly 1,200 consecutive patients presenting to a single UK regional cancer network, 
this represents a large UK report regarding UGI cancer service centralisation. Data 
were contemporaneously and prospectively collected at all local and regional MDT 
meetings over a 4 year period before, during and after centralisation was introduced. 
Survival data are especially robust as no patients were lost to follow-up, while death 
certification was obtained from the Office of National Statistics and data on re-
admissions to critical care and hospital were complete. The significant increase in 
the number of patients to whom potentially curative treatment was offered after 
centralisation is in keeping with findings by Forshaw et al and Boddy et al, but 
contrasts with the findings of Branagan and Davies who reported a similar number of 
patients undergoing resection before and after centralisation (Forshaw et al. 2006; 
Boddy et al. 2012; Branagan et al. 2004). Forshaw et al also reported a reduction in 
cancelled operations due to pressure on ITU beds, similar to our experience. This 
study found the rate of open and close laparotomy procedures decreased slightly 
after centralisation, in keeping with Branagan and Davies (Branagan et al. 2004). 
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The current study also shows length of hospital stay was reduced by a median 2.5 
days, with a significant reduction in ITU length of stay, a similar finding to that 
reported by Chan et al (Chan et al. 2013). Post-operative morbidity (Clavien-Dindo 
≥3) decreased from 23% to 12% post-centralisation, but this was not statistically 
significant. Thirty day post-operative mortality decreased significantly in accordance 
with the findings of Boddy et al who reported 30-day mortality fell from 10.3% to 
3.6%, and with Branagan and Davies who reported operative mortality decreased 
significantly from 15.2% to 0% (p=0.022). These results also resonate with findings 
by Anderson et al who reported high hospital volume significantly and independently 
correlated with improved 30-day post-operative mortality (Anderson et al. 2011). 
Median survival for all patients increased by 11% (9 months vs 10 months, 
p<0.0001) post-centralisation while two year survival rate increased from 23% before 
centralisation to 26% after (p=0.277). The increase in survival reported in this study 
is again in keeping with the findings of Boddy et al who reported after introducing 
centralisation within a UK unit in 2006, and with a systematic review and meta-
analysis performed by Brusselaers et al which looked at sixteen international studies 
and reported a survival benefit in favour of high-volume surgeons (Boddy et al. 2012; 
Brusselaars et al. 2014). The increase in length of survival seen in this study is 
however shorter than that reported elsewhere where median survival times of 2.1 
and 1.5 years were reported for oesophageal and gastric cancers respectively 
(Boddy et al. 2012). Our study population however, included patients from amongst 
the most deprived areas of Wales, with Wales as a whole recognised as having 
relatively high levels of deprivation and an overall life expectancy one year shorter 
when compared with England (National Audit Office 2012). 
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The study does have a number of potential limitations. The data collected from one 
hospital site concerning post-operative surgical outcomes was collected 
retrospectively and may not therefore be as robust as that collected from the other 
two hospital sites. This is mitigated however by the fact that computerised digital 
records recorded all radiological and pathological test results. Furthermore, 
operation notes and discharge summary documentation for these patients, and all 
data from the remaining two hospital sites,  was collected contemporaneously by a 
dedicated clinical research fellow present at all local and regional MDT meetings. 
Also, the direct impact of a contemporaneous ERAS programme could not be 
quantified. Despite showing shorter critical care and total hospital lengths of stay, 
decreased number of re-admissions to ITU, less operative deaths and increased 
survival rates at two years, the study was unable to identify an explicit reason to 
account for these improvements. This was not a randomised controlled trial aimed at 
investigating any single factor or cause and the answer most probably lies in a 
combination of small incremental steps. Allied to better patient selection after 
rigorous radiological investigation and MDT discussion, the cornerstone of such 
improvements could simply be practice – the clinical judgement and technical skill 
achieved only by surgeons frequently performing a specific operation. The combined 
experience and expertise of dedicated radiologists, oncologists, anaesthetists, and 
allied health professionals working within an ERAS programme must also be 
considered. In our experience the median number of operations carried out by the 
individual surgeons increased five-fold, with over 50% carried out by two consultants 
working together. In addition, the study did not examine the impact of co-existing co-
morbidity when considering post-operative morbidity, mortality and length of stay. 
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5.6 Conclusion 
In conclusion, this study involving nearly 1200 consecutive UGI cancer patients 
clearly shows an increased proportion of patients receiving potentially curative 
treatment, fewer cancelled operations, reduced serious post-operative morbidity, 
shortened total length of hospital stay and improved survival, many by significant 
margins. Albeit not a randomised control trial, the results of the study unequivocally 
demonstrate what can be achieved by a UK regional cancer network serving some of 
the most deprived people in the country, The improved morbidity and mortality 
outcomes seen clearly support the centralisation of surgery for upper gastrointestinal 
cancer, and it is the network’s intention to continue follow-up for 5 years in order to 
appreciate the full impact on patient safety and survival bestowed by the introduction 
of a centralised service. 
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Table 5.1 
Demographic details and treatment pre- and post-centralisation (%) 
                                         Pre-centralisation            Post-centralisation              p value 
Total                                            566                                     611 
 
Median age (range), years       73 (22-97)                        72 (24-97)                           0.412 
Gender Male:Female                 379:187 (67:33)              400:211 (65.5:34.5)            0.588  
Oesophageal:Gastric                345:221 (61:39)                347:264 (57:43)                 0.147  
Radiological Stage I                  44 (8)                                 66 (11)                              0.075 
                                II                 81 (14)                              86 (14)                              0.908 
                                III               157 (28)                            133 (22)                             0.018 
                                IV               209 (37)                           272 (46)                             0.008  
                             Unstaged     74 (13)                              37(7)                              <0.0001 
Treatment 
Curative:Palliative                                            
Total                                      129:437 (23:77)                182:429 (30:70)                     0.002 
Oesophageal                           83:262 (24:76)                  118:229 (34:66)                  0.004 
Gastric                                     46:175 (21:79)                  63:201 (24:76)                    0.424 
Definitive Chemoradiotherapy       36 (6)                                46 (8)                            0.432 
Surgery                                         96 (17)                              122 (20)                         0.037 
EMR                                             2 (1.6)                                20 (11)                           0.001                                  
 
Table 5.2 Surgical outcomes pre- and post-centralisation  
[Figures are in numbers (%), lengths of stay are the median in days (range)] 
                                                         Pre (n=85)                Post (n=120)                p value 
Clavien-Dindo grade ≥ 3                   19 (20%)                        15 (13%)                    0.094 
All morbidity                                       32 (33%)                       51 (45%)                    0.078 
Operative (30 day) mortality              5 (5.2%)                         1 (0.9%)                    0.046 
Total hospital stay                            15 (2-72)                        12 (3-53)                    0.008 
High dependency unit stay               1 (0-11)                           1 (0-13)                     0.001 
Intensive therapy unit stay                0 (0-70)                           0 (0-12)                  <0.0001 
Critical care stay                                1 (0-70)                          1 (0-20)                  <0.0001 
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Table 5.3 Univariate analysis of factors associated with 2 year survival 
 
Factor                                   Log Rank                            DF                           p value 
                                                                                                  
 
O-POSSUM Mortality             153.124                             120                            0.022 
Age                                         105.091                               67                            0.002 
Open and Close                         9.470                                1                             0.002 
Centralisation                           10.756                                1                             0.001 
Curative Treatment                403.255                                1                           <0.0001 
rTNM                                      248.104                                4                           <0.0001 
Histology                                  47.276                                7                           <0.0001 
 
DF = Degrees of Freedom 
 
 
Table 5.4 Multivariate analysis of factors associated with 2 year survival 
 
 
Factor                           HR                                       95% CI                            p value 
                                                                                                         
 
rTNM                            1.333                                1.022-1.739                         0.034  
Open and Close           2.460                                1.367-4.430                         0.003 
 
HR = Hazard ratio 
95% CI = 95% Confidence Interval 
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Chapter 6  
General Discussion and Prospect 
The management of oesophago-gastric cancer has evolved significantly in the last 
decade, underpinned by The National Oesophago-Gastric Cancer Audit (NOGCA), a 
collaborative project involving the British Society of Gastroenterology, the 
Association of Upper Gastrointestinal Surgeons, the Royal College of Surgeons of 
England Clinical Effectiveness Unit and the Department of Health. Their collective 
aim is to establish standardised benchmarks for the treatment of UGI cancer and 
identify areas for future improvement. However, despite such a multi-disciplinary and 
stage-directed approach, outcomes remain poor when compared with many other 
malignancies and incurable metastatic disease is still diagnosed in as many as 50% 
of patients at first presentation. For those patients to whom treatment with curative 
intent can be offered, chemotherapy and radiotherapy are associated with significant 
toxicity and morbidity, and radical surgery for oesophageal and gastric tumours are 
among the most physiologically stressful procedures performed. 
By enhancing our understanding of the prognostic factors influencing outcome and 
survival it is hoped further improvements can be achieved. In the current climate of 
the “aggregation of marginal gains” it is clear that improvement will most likely be in 
the form of incremental advances.  This study follows the patient’s journey from the 
time of first noticing significant symptoms through to radiological investigations, 
diagnosis, MDT discussion, treatment, and duration of survival. The idea of 
undertaking this thesis was first considered when recurring trends and observations 
were noted while seeing patients suspected of having, or recently confirmed as 
having, oesophageal or gastric cancer. It was perceived the majority were from more 
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socio-economically deprived areas, who had allowed significant time-lapses before 
first presenting to a medical practitioner by which stage many had incurable disease, 
and many appeared cachectic. It examines a range of demographic, physiological 
and organisational elements influencing a patient’s outcome, and aims to identify 
where amendments can be made and improvements implemented. More specifically 
it addresses the influence of socio-economic and health deprivation, the influence of 
diagnostic delay, the significance of malnutrition, and the impact of centralisation on 
outcome and survival. 
6.1 Prognostic significance of deprivation 
The South East Wales Upper GI cancer MDT manages patients within an area 
encompassing 1.4 million people, many of whom are recognised as living within 
some of the most socio-economically deprived areas of the UK. Deprivation is 
associated with an increased incidence of upper gastrointestinal cancer (McKinney 
et al. 1995; Gossage et al. 2009), and linear relationships between levels of 
deprivation and survival have previously been reported for oesophageal cancer 
(Coleman et al. 1999). Furthermore, a widening of survival inequality with time has 
been reported whereby the improved outcomes experienced by patients living in less 
deprived geographical areas have not been shared by patients from more deprived 
areas (Coleman et al. 2004). In response the NHS Cancer Plan of September 2000, 
and subsequent government targets introduced in 2003, were aimed at reducing 
such inequalities across the socio-economic divide.  
The study supported previous findings indicating that level of socio-economic 
deprivation was strongly associated with adverse outcomes in patients diagnosed 
with UGI cancer, and overall deprivation was associated with duration of survival. 
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Furthermore, despite developing disease at a younger age, being of similar stage of 
disease at diagnosis, and being offered similar treatment protocols, including radical 
surgery, the most deprived patients had significantly shorter median duration of 
survival than the least deprived cohort of patients, notwithstanding these patients 
were offered a more focused input from allied healthcare professionals including 
dieticians and physiotherapists in particular to optimise pre-operative performance. 
The study was unable to identify any particular reason or cause to explain these 
findings, but previously reported increased rates of alcohol and cigarette 
consumption among lower socio-economic classes could be an attributing factor. 
It is of course beyond the realms of this study to solve or provide any easy solutions 
to the perennial problem of deprivation.  At present, whilst the health of society’s 
most deprived population has improved, the gap between the most and least 
deprived has failed to narrow (Dept. of Health 2007, 2009). Previous studies have 
shown that lower socio-economic status is associated with greater delay before first 
presentation (Porta et al. 1996), and this could certainly be a factor explaining the 
decreased survival seen amongst the most deprived. On the understanding that it is 
perhaps an economic impossibility to lift the entire population of a country out of 
deprivation, and particularly in the current climate of economic austerity, the focus 
should therefore be on greater education directed specifically at those residing in 
more deprived geographical areas. This education should focus on topics including 
lifestyle choices, in particular the harm associated with smoking and alcohol excess, 
and on improving early symptom awareness, encouraging prompt visits to one’s 
General Practitioner, and also supporting GPs to appropriately refer patients with 
worrying signs and symptoms as Urgent Suspected Cancers for endoscopy within 14 
days. 
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6.2 Prognostic significance of diagnostic delay 
The timely diagnosis and subsequent treatment of cancer is an increasingly common 
topic for health improvement quality initiatives, and also a frequent theme in the 
media. Indeed, the UK Health Secretary has recently proposed ranking all general 
practices on the NHS Choices website according to how promptly patients 
subsequently diagnosed with cancer were initially referred to specialist services for 
suspected cancer (Malnick 2014). Approximately 80% of patients diagnosed with 
cancer are referred to a hospital specialist after one (50%) or two (30%) GP 
consultations (Lyratzopoulos et al. 2012; Lyratzopoulos et al. 2013), but a substantial 
minority of up to 20% of patients with cancer visit a primary care doctor with relevant 
symptoms three or more times before referral. The European Cancer Registry 
EUROCARE-4 survey showed that the UK ranked 9th and 22nd for male and female 
cancer mortality rates respectively compared with 27 other European countries (de 
Angelis et al. 2009), and late or missed diagnosis has been suggested as a major 
contributor to the UK’s ranking (Dept of Health 2007).  
Patient delay, whereby an individual with symptoms does not seek healthcare advice 
as they attribute vague or non-specific symptoms to everyday explanations such as 
indigestion, or indeed do not identify symptoms such as worsening dysphagia as 
potentially cancer, is thereby prolonged. To address these delays The NHS Cancer 
Plan for England (2000) set out a comprehensive 10 year strategy to improve 
prevention, screening, early diagnosis and treatment for cancer. The Cancer Reform 
Strategy was published in 2007 and set the direction for the next five years, with 
early diagnosis highlighted as one of the most significant challenges to be addressed 
(Dept of Health 2007). Furthermore, The National Awareness and Early Diagnosis 
Initiative (NAEDI) was launched in 2008 with the specific aim of addressing public 
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awareness of cancer, promoting earlier presentation, and reducing primary care 
delay. 
The main findings of this study were that delays in the diagnosis on average 
approached four months, with little improvement having been made when compared 
with a similar study performed in Leeds 20 years ago (Martin et al. 1997). In contrast 
to that study however where practitioner and hospital delay accounted for the 
majority, this study found patient delay was responsible for over 75% of the time 
interval between initial onset of symptoms and diagnosis. Furthermore, deprivation 
and female gender were significantly and independently associated with longer 
patient delays.  
A review of the literature suggests that one of the most important reasons for patient 
delay is symptom misattribution: people who do not identify their symptoms as 
possible indicators of cancer are more likely to delay going to their doctor. Also, fear 
regarding a potential diagnosis of cancer delays people seeking help, with older 
people in particular affected in this regard. Encouraging early presentation is 
essential to tackling patient delay, so initiatives such as NAEDI are therefore key to 
promoting awareness of the early signs and symptoms of cancer among the general 
public and medical practitioners, and particularly those patients living in more 
deprived areas. Patient empowerment is also key, and patients should be 
encouraged to take more control of their care, to ensure they are kept informed, ask 
questions, and seek second opinions if they feel this is warranted. 
 
 
119 
 
6.3 Prognostic significance of Bioelectrical Impedance Analysis  
A review of the literature would indicate that this is the first known study to 
investigate the prognostic significance of BIA-derived body composition parameters 
in oesophago-gastric cancer patients undergoing resection with curative intent. The 
South-East Wales Upper GI Cancer Network serves a population residing in some of 
the most socio-economically deprived areas in the UK, with many patients 
presenting after significant delays (Chapter 3) and with severe consequent 
malnourishment. These patients therefore need particular pre-operative optimisation 
of nutritional status to withstand such surgery and avoid poor outcome. 
The study showed cancer-related malnutrition and catabolism, particularly prevalent 
in UGI cancer, correlated with established pre-, intra-, and post-operative prognostic 
indicators of morbidity and mortality, in keeping with Gupta’s findings in colorectal 
and pancreatic cancer (Gupta et al. 2004). Although a surrogate measurement of 
sarcopenia was used, sarcopenia in particular correlated significantly with surgical 
complications requiring further intervention, and on multivariate analysis was 
independently associated with survival. 
As the prognosis for patients diagnosed with UGI cancer is so often poor, the 
potential benefit from understanding and addressing all reversible factors is 
substantial. With continued patient recruitment over time further research will be 
conducted to investigate oesophageal and gastric cancer patients separately and 
thereby determine whether any particular trends develop when analysed as distinct 
entities. Objective assessments of sarcopenia with CT-measured psoas muscle 
density and body composition will further contribute to the understanding of how 
nutritional status and weight loss can be addressed to improve outcomes. Further 
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research is also warranted to determine allied critical body composition parameters 
such as the phase angle so that enhanced recovery programmes containing 
bespoke nutritional strategies may be developed to improve outcomes and survival.  
This knowledge will guide health policy makers to prioritise funding and provide 
further dietetic support and research into this challenging but ultimately achievable 
goal. 
6.4 Centralisation of Upper GI Cancer Services 
Since first introduced in 2001 the centralisation of oesophageal and gastric cancer 
resection has remained a topic of ongoing debate in contemporary medical literature. 
Centralisation is based on the hypothesis that high volume centres produce better 
short and long term outcomes after research reported a patient’s chances of survival 
increase substantially if operated on by a surgeon performing a specific operation on 
a frequent basis (Birkmeyer et al. 2003). This finding was further supported in a 
subsequent meta-analysis which reported such a survival benefit specifically after 
oesophagectomy (Brusellaars et al. 2014). To date there are 41 specialist centres 
providing UGI cancer care in England and Wales, but despite having been shown to 
significantly improve in-hospital and 30 day mortality, the data regarding long-term 
survival remains limited. A previous report from Wales has shown that centralisation 
resulted in lower morbidity, mortality and length of hospital stay in patients 
undergoing surgery and moreover, one year survival increased in all patients (Chan 
et al. 2013).  
Historically there has been little consensus regarding the possible benefits of either 
centralisation or operative volume on the outcomes of UGI cancer surgery in the UK, 
with particular debate centred on long-term survival. This study, and similar findings 
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by Derogar demonstrate that annual and cumulative surgeon volume are predictors 
of longer term survival and thereby recommend that surgeons should maintain a high 
yearly volume to further optimise prognosis (Derogar et al. 2013). The reasons for 
these documented improvements are multi-factorial; explicit referral protocols, more 
frequent MDT meetings, improved radiological staging and patient selection, and 
improved peri-operative care. A further factor which has received little 
acknowledgement or clinical interest to date however is the benefit of an immediate 
second opinion and an experienced consultant colleague if and when required in 
theatre. In this study in excess of fifty percent of operations were carried out by two 
consultants working together as an operative Consultant team. 
Further to previous findings, this study demonstrated an increased proportion of 
patients receiving potentially curative treatment, fewer cancelled operations, reduced 
post-operative morbidity, shortened total length of hospital stay, and improved 
survival rates, many by significant margins. Furthermore, most of the patients in this 
study reside in areas of significant socio-economic deprivation which could adversely 
influence outcomes. The study thereby clearly supports the centralisation of surgery 
for upper gastrointestinal cancer with strategic national implications for the re-
configuration of similar services in other specialties.  
The 2014 UK National Oesophageal and Gastric Cancer Audit (NOGCA) reported an 
ever-improving service for UGI cancer patients, in particular improved mortality rates, 
improved outcomes after surgery, and other quality indicators of surgery such as 
decreased positive resection margins, thereby further endorsing the centralisation of 
services (NOGCA 2014). Further high quality studies, including the publication of 5 
and 10-year survival rates, identifying which specific aspects of centralisation 
improve outcome, and the cost-effectiveness in terms of quality-adjusted life years, 
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are needed in order to appreciate the full impact on patient safety and survival 
bestowed by the introduction of a centralised service. This data will also inform policy 
decision makers in the future re-organisation of cancer services. 
6.5 Conclusion 
A diagnosis of oesophago-gastric cancer is still thought of as the sounding of the 
death knell by many patients and clinicians alike, indeed gastric cancer was 
commonly described as one of the “captains of men of death”. This thesis set out to 
identify potential prognostic indicators for people diagnosed with these cancers, and 
furthermore identify whether these factors are reversible. While demographic factors 
such as one’s level of socio-economic deprivation are not amenable to any rapid 
amelioration, enhanced public awareness of the signs and symptoms associated 
with UGI cancer are however more feasible, as are systemic changes such as 
further funding for general public and clinician education programmes, more 
expedient diagnosis procedures, further centralisation of cancer care, and greater 
support for patients undergoing surgery in particular addressing nutritional 
deficiencies.  A recent innovation in Cardiff is the ‘Fit for List’ health screen which 
includes an array of simple tests and interventions to be used by GPs and specialist 
nurses to facilitate the early detection of problems such as high blood pressure or 
anaemia at the time of initial referral and thereby optimise the patient before they 
undergo their cancer treatment and prevent any potential delays. To date there has 
been significant improvement in the fate of patients diagnosed with UGI cancer, and 
the focus at present is centred on incremental improvements but there are still hard 
yards to be fought and won. The hypotheses and results generated in this thesis 
should be further built upon to improve treatment algorithms and outcome for 
patients diagnosed with oesophago-gastric cancer. 
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